United Cannabis (CNABQ) 10-K 15 Apr 15 2014 FY Annual report Financial data

Document_and_Entity_Informatio

Document and Entity Information (USD $)	12 Months Ended
	Dec. 31, 2014	Apr. 14, 2015	Jun. 30, 2014
Document and Entity Information [Abstract]
Entity Registrant Name	United Cannabis Corp
Entity Central Index Key	1436161
Document Type	10-K
Document Period End Date	31-Dec-14
Amendment Flag	FALSE
Current Fiscal Year End Date	-19
Entity Well-known Seasoned Issuer	No
Entity Voluntary Filers	No
Entity Current Reporting Status	Yes
Entity Filer Category	Smaller Reporting Company
Entity Public Float			$8,796,600
Entity Common Stock, Shares Outstanding		44,711,000
Document Fiscal Period Focus	FY
Document Fiscal Year Focus	2014

CONSOLIDATED_BALANCE_SHEETS

CONSOLIDATED BALANCE SHEETS (USD $)	Dec. 31, 2014	Dec. 31, 2013
Current assets:
Cash and cash equivalents	$321,353	$32,414
Accounts receivable	6,245
Due from related parties	44,012	8,862
Prepaid expenses	177,400
Assets of discontinued operations		17,616
Total current assets	549,010	58,892
Intangible assets	18,210
Investments in non-marketable equity securities	593,750
Equity method investments	138,000
Total assets	1,298,970	58,892
Current liabilities:
Accounts payable	27,424
Accrued expenses	550,795
Current portion of deferred revenue	500,000
Notes payable	775,000
Convertible note payable, related party		50,000
Total current liabilities	1,853,219	50,000
Long term liabilities:
Deferred revenue, net of current portion	443,750
Total liabilities	2,296,969	50,000
Stockholders' (deficit) equity:
Preferred stock, no par value; 10,000,000 shares authorized; none issued and outstanding
Common stock, no par value; 100,000,000 shares authorized; 44,020,000 and 6,020,000 shares issued and outstanding, respectively	1,538,968	165,495
Common stock outstanding, not yet issued; 40,000 shares	88,000
Accumulated deficit	-2,624,967	-156,603
Total stockholders' (deficit) equity	-997,999	8,892
Total liabilities and stockholders' (deficit) equity	$1,298,970	$58,892

CONSOLIDATED_BALANCE_SHEETS_Pa

CONSOLIDATED BALANCE SHEETS (Parenthetical) (USD $)	Dec. 31, 2014	Dec. 31, 2013
CONSOLIDATED BALANCE SHEETS [Abstract]
Preferred stock, no par value
Preferred stock, shares authorized	10,000,000	10,000,000
Preferred stock, shares issued
Preferred stock, shares outstanding
Common stock, no par value
Common stock, shares authorized	100,000,000	100,000,000
Common stock, shares issued	44,020,000	6,020,000
Common stock, shares outstanding	44,020,000	6,020,000
Common stock, not yet issued shares	40,000	40,000

CONSOLIDATED_STATEMENTS_OF_OPE

CONSOLIDATED STATEMENTS OF OPERATIONS (USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013
Revenues:
Revenues, non-affiliates	$171,957
Revenues, affiliate	14,600
Total revenues	186,557
Cost of revenues	7,031
Gross profit	179,526
Operating expenses:
Sales and marketing	101,962
Research and development	182,606
General and administrative	1,709,040	33,661
Total operating expenses	1,993,608	33,661
Loss from operations	-1,814,082	-33,661
Other income (expense):
Interest income	37,837
Gain on derivative liability	6,099
Loss on origination of derivative liability	-12,810
Interest expense	-131,479
Amortization of debt discount	-161,402
Loss on extinguishment of debt and repurchase of warrants	-33,635
Loss on investment in non-marketable equity securities	-300,000
Total other income (expense)	-595,390
Loss from continuing operations	-2,409,472	-33,661
Net income (loss) from discontinued operations	-58,892	30,496
Net loss	($2,468,364)	($3,165)
Net loss per share from continuing operations:
Basic and diluted	($0.06)	($0.01)
Net income (loss) per share from discontinued operations:
Basic and diluted	$0	$0.01
Net loss per common share:
Basic and diluted	($0.06)	$0
Basic and diluted weighted-average common shares outstanding:	38,256,438	6,020,000

CONSOLIDATED_STATEMENTS_OF_STO

CONSOLIDATED STATEMENTS OF STOCKHOLDERS' (DEFICIT) EQUITY (USD $)	Total	Common Stock [Member]	Accumulated Deficit [Member]
Beginning balance at Dec. 31, 2012	$12,057	$165,495	($153,348)
Beginning balance, shares at Dec. 31, 2012		6,020,000
Net loss	-3,165		-3,165
Ending balance at Dec. 31, 2013	8,892	165,495	-156,603
Ending balance, shares at Dec. 31, 2013		6,020,000
Shares issued for conversion of debt	50,000	50,000
Shares issued for conversion of debt, shares		40,000,000
Shares cancelled
Shares cancelled, shares		-41,690,000
Shares issued for license agreement
Shares issued for license agreement, shares		38,690,000
Shares and warrants issued for cash	900,000	900,000
Shares and warrants issued for cash, shares		600,000
Warrants issued with convertible debt	694,525	694,525
Warrants issued with convertible debt, shares
Shares issued for services	305,100	305,100
Shares issued for services, shares		400,000
Purchase and cancellation of warrants	-576,152	-576,152
Purchase and cancellation of warrants, shares
Shares not yet issued for equity method investments	88,000	88,000
Shares not yet issued for equity method investments, shares		40,000
Net loss	-2,468,364		-2,468,364
Ending balance at Dec. 31, 2014	($997,999)	$1,626,968	($2,624,967)
Ending balance, shares at Dec. 31, 2014		44,060,000

CONSOLIDATED_STATEMENTS_OF_CAS

CONSOLIDATED STATEMENTS OF CASH FLOWS (USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013
Operating activities:
Net loss	($2,468,364)	($3,165)
Adjustments to reconcile net loss to net cash provided by (used in) operating activities:
Depreciation - assets of discontinued operations		18,019
Loss on sale of assets of discontinued operations	15,704
Management fees and reimbursement of expenses, related parties, net, of discontinued operations		-3,465
Amortization of debt discount	161,402
Non-cash interest expense	15,320
Notes payable issued for debt issuance costs	46,000
Loss on origination of derivative liability	12,810
Share-based compensation	551,685
Value of non-marketable equity securities recognized as revenue	-150,000
Gain on revaluation of derivative liability	-6,099
Loss on non-marketable equity securities	300,000
Loss on extinguishment of debt and repurchase of warrants	33,635
Changes in operating assets and liabilities:
Accounts receivable	-6,245
Due from related party	-33,238
Inventory		-3,026
Prepaid expenses	-6,321
Accounts payable and accrued expenses	144,654	-34,179
Deferred revenue	200,000
Net cash provided by (used in) operating activities	-1,189,057	-25,816
Investing activities:
Purchase of intangible assets	-2,309
Purchase of equity method investments	-50,000
Purchase of equipment related to discontinued operations		-18,215
Net cash provided by (used in) investing activities	-52,309	-18,215
Financing activities:
Net proceeds from issuance of notes payable	761,500
Net proceeds from issuance of convertible debt and warrants	225,000
Repayment of convertible debt and repurchase of warrants	-356,195
Proceeds from convertible note payable, related party		50,000
Repayment of notes payable, related party		-50,000
Proceeds from issuance of common shares and warrants	900,000
Net cash provided by (used in) financing activities	1,530,305
Net increase (decrease) in cash	288,939	-44,031
Cash, beginning of period	32,414	76,445
Cash, end of period	321,353	32,414
Supplemental schedule of cash flow information:
Cash paid for interest
Cash paid for income taxes
Supplemental disclosure of non-cash investing and financing activities:
Intangible asset costs included in accounts payable	15,901
Non-marketable equity securities received as consideration for future services	893,750
Equity method investments received for commitment to issue common stock	88,000
Issuance of common stock for services	83,600
Issuance of common stock for prepaid professional fees	221,500
Issuance of note payable for debt issuance costs	13,500
Issuance of convertible note payable for debt issuance costs	32,500
Warrants issued for debt discount	694,525
Warrants cancelled	576,152
Debt conversion feature issued for debt discount	151,937
Debt conversion feature issued for interest payable discount
Conversion of note payable, related party, into common stock	$50,000

BUSINESS_ORGANIZATION_AND_NATU

BUSINESS ORGANIZATION AND NATURE OF OPERATIONS	12 Months Ended
	Dec. 31, 2014
BUSINESS ORGANIZATION AND NATURE OF OPERATIONS [Abstract]
BUSINESS ORGANIZATION AND NATURE OF OPERATIONS	NOTE 1 –BUSINESS ORGANIZATION AND NATURE OF OPERATIONS
	On March 19, 2014, we effected a four-for-one stock split of our outstanding shares of common stock. All references to shares of our common stock in our consolidated financial statements refer to the number of shares of common stock after giving effect to the stock split (unless otherwise indicated).
	Background and Current Operations
	United Cannabis Corporation ("we", "our", "us", "UCANN", or "the Company") a Colorado corporation, was originally formed as a California corporation under the name MySkin, Inc. on November 15, 2007. MySkin was engaged in the business of providing management services to a medical spa in Los Angeles, California which provided various advanced skin care services until March 31, 2014, when this business was sold to the prior President of the Company.
	In early 2014 we decided to exit the medical spa management business and change our focus to providing products, services and intellectual property to the cannabis industry.
	On March 26, 2014, we entered into a License Agreement with Earnest Blackmon, Tony Verzura and Chad Ruby pursuant to which Messrs. Blackmon, Verzura and Ruby licensed certain intellectual property to us in exchange for a total of 38,690,000 shares of our common stock.
	In connection with this transaction:
		Messrs. Blackmon, Verzura and Ruby licensed to us all of their knowledge and know-how relating to the design and buildout of cultivation facilities, growing/cultivation systems, seed-to-sale protocols and procedures, products, a genetic catalogue including over 150 different strains, an advanced (non-psychoactive) cannabinoid therapy program called "A.C.T. Now", security, regulatory compliance, and other methods and processes which relate to the cannabis industry.
		The territory for this license is the entire world and the license runs in perpetuity. There are no royalty payments under the License Agreement.
		Messrs. Blackmon, Verzura and Ruby were appointed to our board of directors effective April 7, 2014.
		Mr. Blackmon was elected as our President, Mr. Ruby was elected as Chief Operating Officer and Mr. Verzura was elected as Vice President.
		A total of 41,690,000 previously outstanding shares of common stock were cancelled resulting in a total of 43,620,000 shares of common stock outstanding on March 26, 2014.
	UCANN was formed as a Colorado corporation on March 25, 2014, and on May 2, 2014, MySkin, Inc. merged into UCANN, a wholly-owned subsidiary of MySkin, Inc., for the purpose of changing domicile from California to Colorado and changing the corporation's name to United Cannabis Corporation.
	On March 31, 2014, we sold all right, title and interest in the tangible and intangible assets, trademarks, customer lists, intellectual property and rights, which we owned and were related to our advanced skin care business since we have entered into a new business and no longer have any use for these assets. The assets were sold to MySkin Services, Inc. (“MTA”), a business partly owned by Marichelle Stoppenhagen, our former officer and director, in exchange for the $15,000 payable which we owed to Ms. Stoppenhagen and/or MTA.  In addition, MTA assumed all costs associated with these assets starting on March 31, 2014.
	Government Regulation - Marijuana is a Schedule-I controlled substance and is illegal under federal law. Even in those states in which the use of marijuana has been legalized, its use remains a violation of federal laws.
	As of March 31, 2015, 23 states and the District of Columbia allow their citizens to use medical marijuana, and voters in the states of Colorado, Washington, Oregon, Alaska and the District of Columbia approved ballot measures to legalize cannabis for adult recreational use.  The state laws are in conflict with the federal Controlled Substances Act, which makes marijuana use and possession illegal on a national level. The Obama administration has effectively stated that it is not an efficient use of resources to direct federal law enforcement agencies to prosecute those lawfully abiding by state-designated laws allowing the use and distribution of medical and recreational marijuana. However, there is no guarantee that the current administration will not change its stated policy regarding the low-priority enforcement of federal laws, or that any future administration would not change this policy and decide to enforce the federal laws vigorously.  Any such change in the federal government's enforcement of current federal laws could cause significant financial damage to us.

SUMMARY_OF_SIGNIFICANT_ACCOUNT

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES	12 Months Ended
	Dec. 31, 2014
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES [Abstract]
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES	NOTE 2 – SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
	Principles of Consolidation - Our consolidated financial statements include our accounts and the accounts of our wholly-owned subsidiary UC Nevada L.L.C. All intercompany accounts and transactions have been eliminated. Our consolidated financial statements are stated in United States dollars and have been prepared in accordance with accounting principles generally accepted in the United States (“U.S. GAAP”).
	Use of Estimates - The preparation of our consolidated financial statements in conformity with U.S. GAAP requires us to make estimates, assumptions and judgments that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities as of the date of our consolidated financial statements and the reported amounts of revenues expenses during the periods presented.
	We make our estimate of the ultimate outcome for these items based on historical trends and other information available when our consolidated financial statements are prepared. We recognize changes in estimates in accordance with the accounting rules for the estimate, which is typically in the period when new information becomes available. We believe that our significant estimates, assumptions and judgments are reasonable, based upon information available at the time they were made. Our actual results could differ from these estimates, making it possible that a change in these estimates could occur in the near term.
	Financial Instruments – We have adopted Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) 825, Financial Instruments, which requires disclosures of information about the fair value of certain financial instruments for which it is practicable to estimate that value. For purposes of this disclosure, the fair value of a financial instrument is the amount at which the instrument could be exchanged in a current transaction between willing parties, other than in a forced sale or liquidation.
	The carrying amounts of our short-term financial instruments, including accounts receivable, prepaid expenses, accounts payable, accrued expenses and deferred revenue approximates fair value due to the relatively short period to maturity for these instruments. Investments in non-marketable equity securities are carried at cost. The carrying amount of our notes payable at December 31, 2014, approximates their fair values based on our incremental borrowing rates.
	Cash and Cash Equivalents - We consider investments with original maturities of 90 days or less to be cash equivalents. We do not have cash equivalents as of December 31, 2014 and 2013.
	Accounts Receivable – Our accounts receivable consists primarily of trade accounts arising in the normal course of business. No interest is charged on past due accounts. Accounts for which no payments have been received after 30 days are considered delinquent and customary collection efforts are initiated. Accounts receivable are carried at original invoice amount less a reserve made for doubtful accounts based on a review of all outstanding amounts on a monthly basis.
	We determine our allowance for doubtful accounts by regularly evaluating individual customer receivables and considering the customer's financial condition and credit history, and current economic conditions. Based on our analysis, no allowance for doubtful accounts was necessary as of December 31, 2014 and 2013.
	Inventory - Inventory is valued at the lower of cost or market. Cost is determined using standard costs, which approximates the first-in, first-out method.
	Property and Equipment –Our property and equipment are recorded at cost. Maintenance and repairs are expensed as incurred. Depreciation is computed using the straight-line method over an estimated useful life of three to five years. Assets acquired under capital leases are depreciated over the lesser of the useful life of the asset or the lease term. At the time of retirement or other disposition of property and equipment, the cost and accumulated depreciation are removed from our accounts and any resulting gain or loss is reflected in our consolidated statements of operations.
	Intangible Assets – Our intangible assets, consisting of trademark, design mark and provisional patent applications are recorded at cost, and once approved, are amortized using the straight-line method over an estimated useful life of 10 to 20 years.
	Investments in Non-Marketable Equity Securities – Our investments in non-marketable equity securities are carried at cost, less write-down-for-impairments, and are adjusted for impairment based on methodologies, including the valuation achieved in the most recent private placement by the investee, an assessment of the impact of general private equity market conditions, and discounted projected future cash flows. Investments in non-marketable equity securities that expire in less than 12 months, for example stock options or warrants, are classified as current assets; otherwise, we classify investments in non-marketable equity securities as other noncurrent assets.
	Long-Lived Assets – Our intangible assets and other long-lived assets are subject to an impairment test if there is an indicator of impairment. The carrying value and ultimate realization of these assets is dependent upon our estimates of future earnings and benefits that we expect to generate from their use. If our expectations of future results and cash flows are significantly diminished, intangible assets and other long-lived assets may be impaired and the resulting charge to operations may be material. When we determine that the carrying value of intangibles or other long-lived assets may not be recoverable based upon the existence of one or more indicators of impairment, we use the projected undiscounted cash flow method to determine whether an impairment exists, and then measure the impairment using discounted cash flows.
	Equity Method Investments – Our investments in entities representing ownership of at least 20% but less than 50%, where we exercise significant influence, are accounted for under the equity method.
	Deferred Revenue - We defer revenue for which product or service has not yet been delivered or is subject to refund until such time that we and our customer jointly determine that the product or service has been delivered or no refund will be required.
	Revenue Recognition - We recognize revenue in accordance with ASC 605, Revenue Recognition, which requires that four basic criteria must be met before revenue can be recognized: (1) persuasive evidence of an arrangement exists; (2) delivery has occurred; (3) the selling price is fixed and determinable; and (4) collectability is reasonably assured. Determination of criteria (3) and (4) are based on our management's judgments regarding the fixed nature of the selling prices of the products and services delivered and the collectability of those amounts.
	Revenue for services with a payment in form of stock, warrants or other financial assets is recognized when the services are performed. The value of revenue is measured using the Black-Scholes model for warrants.
	Cost of Revenues - Our cost of revenues consists primarily of costs associated with the production and delivery of our products and services. These include expenses related to the production, packaging and labeling of our Prana medicinals products and consulting expense related to our advisory services.
	Advertising Costs - All advertising costs are expensed as incurred.
	Research and Development Expenses - Research and development (“R&D”) costs are charged to expense as incurred. Our R&D costs include, but are not limited to, consulting service fees and materials and supplies used in the development of our proprietary products and services.
	Selling, General and Administrative Expenses - Selling, general and administrative expenses consist primarily of personnel-related costs, rent, corporate costs, fees for professional and consulting services, advertising costs, and other costs of administration such as marketing, human resources, finance and administrative roles.
	Stock-Based Compensation - We periodically issue shares of our common stock to non-employees in non-capital raising transactions for fees and services. We account for stock issued to non-employees in accordance with ASC 505, Equity, whereas the value of the stock compensation is based upon the measurement date as determined at either (a) the date at which a performance commitment is reached, or (b) at the date at which the necessary performance to earn the equity instruments is complete.
	We account for stock option grants issued and vesting to employees based on ASC 718, Compensation – Stock Compensation, whereas the award is measured at its fair value at the date of grant and is amortized ratably over the vesting period. Accounting for stock-based compensation to employees requires the measurement and recognition of compensation expense for all share-based payment awards made to employees based on estimated fair values. We estimate the fair value of all stock option awards on the date of grant using the Black-Scholes-Merton pricing model, which is affected by our stock price, as well as assumptions regarding a number of complex and subjective variables. These variables include our expected stock price volatility over the term of the awards, actual and projected employee option exercise behaviors, risk free interest rates and expected dividends. We also estimate forfeitures at the time of grant and revise those estimates in subsequent periods if actual forfeitures differ from our estimates.
	Income Taxes - Income taxes are recorded using the asset and liability method. Under the asset and liability method, tax assets and liabilities are recognized for the tax consequences attributable to differences between financial statement carrying amounts of existing assets and liabilities and their respective tax bases. Future tax assets and liabilities are measured using the enacted tax rates expected to apply when the asset is realized or the liability settled. The effect on future tax assets and liabilities of a change in tax rates is recognized in income in the period that enactment occurs. To the extent that we do not consider it more likely than not that a future tax asset will be recovered, we will provide a valuation allowance against the excess.
	We follow the provisions of ASC 740, Income Taxes. As a result of the ASC 740, we make a comprehensive review of our portfolio of tax positions in accordance with recognition standards established by ASC 740. As a result of the implementation of ASC 740, we recognized no material adjustments to liabilities or stockholders' (deficit) equity.
	When tax returns are filed, it is highly certain that some positions taken would be sustained upon examination by the taxing authorities, while others are subject to uncertainty about the merits of the position taken or the amount of the position that would be ultimately sustained. The benefit of a tax position is recognized in our consolidated financial statements in the period during which, based on all available evidence, we believe it is more likely than not that the position will be sustained upon examination, including the resolution of appeals or litigation processes, if any. Tax positions taken are not offset or aggregated with other positions. Tax positions that meet the more-likely-than-not recognition threshold are measured as the largest amount of tax benefit that is more than 50 percent likely of being realized upon settlement with the applicable taxing authority. The portion of the benefits associated with tax positions taken that exceeds the amount measured as described above is reflected as a liability for unrecognized tax benefits in the accompanying consolidated balance sheets along with any associated interest and penalties that would be payable to the taxing authorities upon examination.
	Interest and penalties associated with unrecognized tax benefits, if any, are classified as interest expense and penalties and are included in selling, general and administrative expenses in our consolidated statements of operations.
	Commitments and Contingencies - Certain conditions may exist as of the date our consolidated financial statements are issued, which may result in a loss but which will only be resolved when one or more future events occur or fail to occur.  We assess such contingent liabilities, and such assessment inherently involves an exercise of judgment.  In assessing loss contingencies related to legal proceedings that are pending against us or unasserted claims that may result in such proceedings, we evaluate the perceived merits of the legal proceedings or unasserted claims as well as the perceived merits of the amount of relief sought or expected to be sought therein.
	If the assessment of a contingency indicates that it is probable that a material loss has been incurred and the amount of the liability can be estimated, then the estimated liability would be accrued in our consolidated financial statements.  If the assessment indicates that a potentially material loss contingency is not probable, but is reasonably possible, or is probable but cannot be estimated, then the nature of the contingent liability, together with an estimate of the range of possible loss if determinable and material, would be disclosed.
	Loss contingencies considered remote are generally not disclosed unless they involve guarantees, in which case the nature of the guarantee would be disclosed.
	Net Income (Loss) Per Share - We compute net income (loss) per share in accordance with ASC 260, Earnings per Share. Under the provisions of ASC 260, basic net income (loss) per share includes no dilution and is computed by dividing the net income (loss) available to common stockholders for the period by the weighted average number of shares of common stock outstanding during the period. Diluted net income (loss) per share takes into consideration shares of common stock outstanding (computed under basic net income (loss) per share) and potentially dilutive securities that are not anti-dilutive.
	Potentially dilutive securities outlined in the table below have been excluded from the computation of diluted net loss per share, because the effect of their inclusion would have been anti-dilutive.
		Years Ended December 31,
		2014			2013
	Warrants to purchase common stock		3,170,044			—
	Other Comprehensive Income (Loss) – We report as other comprehensive income (loss) those revenues, gains and losses not included in the determination of net income.  During the years ended December 31, 2014 and 2013, we did not have any gains and losses resulting from activities or transactions that resulted in comprehensive income or loss.
	Segment Reporting – UCANN operates as one segment.
	Concentration of Credit Risk - Financial instruments that potentially subject us to credit risk consist of cash. We maintain our cash with high credit quality financial institutions; at times, such balances with any one financial institution may not be insured by the FDIC.
	The following tables show significant concentrations in our revenues and accounts receivable for the periods indicated:
	Percentage of Revenue:
		Years Ended December 31,
		2014			2013
	Customer A		80	%		—	%
	Percentage of Accounts Receivable:
		Years Ended December 31,
		2014			2013
	Customer B		46	%		—	%
	Customer C		33	%		—	%
	Customer D		21	%		—	%
	Recently Issued Accounting Pronouncements - From time to time, the FASB or other standards setting bodies issue new accounting pronouncements. Updates to the FASB ASCs are communicated through issuance of an Accounting Standards Update ("ASU"). Unless otherwise discussed, we believe that the impact of recently issued guidance, whether adopted or to be adopted in the future, is not expected to have a material impact on our consolidated financial statements upon adoption.
	In May 2014 the FASB issued guidance on revenue from contracts with customers, which implements a five step process of how an entity should recognize revenue in order to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. This guidance will be effective at the beginning of fiscal year 2018, and early application is not permitted. The standard permits the use of either the retrospective or cumulative effect transition method. We are currently evaluating the impact that the adoption will have on our consolidated financial statements and related disclosures. We have not yet selected a transition method nor have we determined the effect of the standard on our ongoing reporting.

GOING_CONCERN

GOING CONCERN	12 Months Ended
	Dec. 31, 2014
GOING CONCERN [Abstract]
GOING CONCERN	NOTE 3 – GOING CONCERN
	Our consolidated financial statements have been prepared on a going concern basis which assumes we will be able to realize our assets and discharge our liabilities in the normal course of business for the foreseeable future. During the year ended December 31, 2014, we incurred losses of $2,468,364 and used cash of $1,189,057 in our operating activities. As at December 31, 2014, we had a working capital deficit of $1,304,209 and an accumulated deficit of $2,624,967.  Our ability to continue as a going concern is dependent upon our ability to generate profitable operations in the future and, or, obtaining the necessary financing to meet our obligations and repay our liabilities arising from normal business operations when they come due. There is no assurance that these events will be satisfactorily completed.

INVESTMENTS_IN_NONMARKETABLE_E

INVESTMENTS IN NON-MARKETABLE EQUITY SECURITIES	12 Months Ended
	Dec. 31, 2014
INVESTMENTS IN NON-MARKETABLE EQUITY SECURITIES [Abstract]
INVESTMENTS IN NON-MARKETABLE EQUITY SECURITIES	NOTE 4 – INVESTMENTS IN NON-MARKETABLE EQUITY SECURITIES
	On June 9, 2014, we received 1,187,500 common shares and 3,000,000 warrants to purchase common shares of WeedMD RX Inc. (“WMD”), a private Canadian company in the cannabis industry, in exchange for future consulting services and use of our intellectual property. The shares represented a 4.29% equity investment in WMD at the time of the investment and we do not have significant influence over the investee. We recorded our investment in these non-marketable equity securities at estimated cost, based on our estimate of the fair value of the securities on the date of the transaction.
	The WMD common shares were recorded at $0.50 per share based on WMD's most recent sale of their common shares prior to the date of the transaction (CAD $0.50). The $593,750 cost assigned is classified as investment in non-marketable equity securities on our consolidated balance sheets.
	The warrants entitled us to purchase WMD shares for CAD $0.50 each for a period of six months from the date the warrant was issued.
	The WMD warrants were recorded at $0.10 per warrant utilizing the Black Scholes option pricing model and the following assumptions on the date of valuation:
	Risk free interest rate	0.6	%
	Expected term (years)	0.5
	Expected volatility	70	%
	Expected dividends	0	%
	On December 9, 2014, the 3,000,000 WMD warrants expired unexercised and we recorded a $300,000 loss on investment in non-marketable equity securities in our consolidated statements of operations.

PREPAID_EXPENSES

PREPAID EXPENSES	12 Months Ended
	Dec. 31, 2014
PREPAID EXPENSES [Abstract]
PREPAID EXPENSES	NOTE 5 – PREPAID EXPENSES
	Our prepaid expenses consist of:
		December 31,
		2014		2013
	Prepaid investor relations services	$	121,500	$	—
	Other prepaid services and fees		55,900		—
		$	177,400	$	—

EQUIPMENT

EQUIPMENT	12 Months Ended
	Dec. 31, 2014
EQUIPMENT [Abstract]
EQUIPMENT	NOTE 6 – EQUIPMENT
	Our equipment, included in assets of discontinued operations on our consolidated balance sheets, consists of:
		December 31,
		2014		2013
	Equipment	$	—	$	131,584
	Less accumulated depreciation		—		(113,968	)
		$	—	$	17,616

INTANGIBLES

INTANGIBLES	12 Months Ended
	Dec. 31, 2014
INTANGIBLES [Abstract]
INTANGIBLES	NOTE 7 – INTANGIBLES
	Our intangible assets are comprised of a provisional patent application and applications for a design mark and trademarks. Our intangible assets will be amortized on a straight-line basis over estimated useful lives of 20 years for patents and 10 years for design marks and trademarks once the applications are approved. Costs associated with applications that are not approved will be expensed in the period that the application is rejected or abandoned.

EQUITY_METHOD_INVESTMENTS

EQUITY METHOD INVESTMENTS	12 Months Ended
	Dec. 31, 2014
EQUITY METHOD INVESTMENTS [Abstract]
EQUITY METHOD INVESTMENTS	NOTE 8 – EQUITY METHOD INVESTMENTS
	Our equity method investments consist of:
		December 31,
		2014		2013
	Lone Mountain Partners, LLC – 25% interest	$	50,000	$	—
	Cannabinoid Research & Development Company Limited – 50%		88,000		—
	Total equity method investments	$	138,000	$	—
	On August 14, 2014, we acquired a 25% membership interest in Lone Mountain Partners, LLC, (“Lone Mountain”) for $50,000 and a commitment to provide future services, including, but not limited to, assisting with the application to obtain licenses to operate a medical marijuana entity in Nevada and to provide  standard operating procedures, security protocols, extract processing and equipment design, cultivation and processing center management, staffing and assistance with ongoing management of Lone Mountain. As of December 31, 2014, Lone Mountain did not have any operations or operating activities. We accounted for our $50,000 cash contribution as an equity method investment on our consolidated balance sheets.
	On August 15, 2014, we acquired a 50% interest in Cannabinoid Research & Development Company Limited (“CRD”), a Jamaican company, in exchange 40,000 shares of our common stock valued at $88,000 based on the previous day's closing price of our stock. We also committed to provide expertise on design-build, genetics, cultivation, production, processing, productizing, labeling, packaging, marketing, branding and distribution of products, as well as use of our intellectual property in the operations of CRD. As of December 31, 2014, CRD did not have any operations or operating activities. We accounted for this $88,000 as an equity method investment on our consolidated balance sheets. As we have not yet issued the 40,000 shares, the $88,000 is classified as common stock not yet issued on our consolidated balance sheets.

NOTES_RECEIVABLE_AND_INTEREST_

NOTES RECEIVABLE AND INTEREST INCOME	12 Months Ended
	Dec. 31, 2014
NOTES RECEIVABLE AND INTEREST INCOME [Abstract]
NOTES RECEIVABLE AND INTEREST INCOME	NOTE 9 – NOTES RECEIVABLE AND INTEREST INCOME
	Notes Receivable
	On August 13, 2014, in conjunction with the $1,657,500 Typenex Co-Investment, LLC (“Typenex”) convertible promissory note more fully described in Note 14 below, we received five, unsecured, $250,000 Investor Notes bearing interest at 8% per annum, totaling $1,250,000 that were scheduled to mature with respect to principal and interest on September 13, 2016. On December 29, 2014, we settled the amounts owing under the convertible promissory note and the amounts owed to us under the Investor Notes as more fully described in Note 14 below.
	Interest Income
	During the year ended December 31, 2014, we recognized $37,807 of interest income applicable to these Investor Notes.

ACCRUED_EXPENSES

ACCRUED EXPENSES	12 Months Ended
	Dec. 31, 2014
ACCRUED EXPENSES [Abstract]
ACCRUED EXPENSES	NOTE 10 – ACCRUED EXPENSES
	Our accrued expenses consist of:
		December 31,
		2014		2013
	Accrued consulting fees	$	110,000	$	—
	Accrued wages and related		433,963		—
	Accrued interest expense		6,832		—
	Total accrued expenses	$	550,795	$	—

FAIR_VALUE_MEASUREMENTS_AND_DE

FAIR VALUE MEASUREMENTS AND DERIVATIVE LIABILITY	12 Months Ended
	Dec. 31, 2014
FAIR VALUE MEASUREMENTS AND DERIVATIVE LIABILITY [Abstract]
FAIR VALUE MEASUREMENTS AND DERIVATIVE LIABILITY	NOTE 11 – FAIR VALUE MEASUREMENTS AND DERIVATIVE LIABILITY
	We have adopted the guidance of ASC 820, Fair Value Measurement, which clarifies the definition of fair value, prescribes methods for measuring fair value, and establishes a fair value hierarchy to classify the inputs used in measuring fair value as follows:
	Level 1-Inputs are unadjusted quoted prices in active markets for identical assets or liabilities available at the measurement date.
	Level 2-Inputs are unadjusted quoted prices for similar assets and liabilities in active markets, quoted prices for identical or similar assets and liabilities in markets that are not active, inputs other than quoted prices that are observable, and inputs derived from or corroborated by observable market data.
	Level 3-Inputs are unobservable inputs which reflect the reporting entity's own assumptions on what assumptions the market participants would use in pricing the asset or liability based on the best available information.
	We valued our derivative liability related to embedded conversion features applicable to our initial borrowing of $282,500 under the Typenex convertible note payable (see Note 14 below) and accrued interest payable of $28,473 thereon in accordance with the Level 3 guidelines. For the year ended December 31, 2014, the following table reconciles the beginning and ending balances for our financial instruments that are carried at fair value measured on a recurring basis:
	Derivative liability as of December 31, 2013	$	—
	Additions to derivative liability for convertible debt conversion feature recorded as debt discount		151,937
	Additions to derivative liability for interest payable conversion feature recorded as interest expense		15,320
	Gain on revaluation of derivative liability during the year		(6,099	)
	Settlement of derivative liability on December 29, 2014		(161,158	)
	Derivative liability as of December 31, 2014	$	—
	The fair values of embedded conversion features issued with our convertible debt and accrued interest payable were estimated using the Black-Scholes option pricing model. The key inputs to this valuation model during the year ended December 31, 2014, were as follows:
	Risk-free interest rate	0.43% – 0.72%
	Dividend yield	—
	Volatility	146%–172%
	Expected life in years	1.72–2.09
	Exercise price	$3.00
	We did not have any financial instruments carried at fair value measured on a recurring basis as of December 31, 2013, and all liabilities incurred and carried at fair value on a recurring basis during 2014 were settled as of December 31, 2014.

DEFERRED_REVENUE

DEFERRED REVENUE	12 Months Ended
	Dec. 31, 2014
DEFERRED REVENUE.
DEFERRED REVENUE.	NOTE 12 – DEFERRED REVENUE
	Our deferred revenue consists of:
		December 31,
			2014		2013
	Deferred revenue – WeedMD	$	743,750		$	—
	Deferred revenue - FoxBarry		200,000			—
	Less – current portion		(500,000	)		—
	Deferred revenue, net of current portion	$	443,750		$	—
	As described in Note 4 above, on June 9, 2014, we received 1,187,500 common shares and 3,000,000 warrants to purchase common shares of WMD in exchange for future consulting services and use of our intellectual property. We recorded the $893,750 fair value of these securities as deferred revenue and, based on discussions with WMD, we expect to deliver consulting services and use of our intellectual property to WMD on a consistent monthly basis during a three year period beginning June 1, 2014. Accordingly, we began recognizing $25,000 of deferred revenue per month totaling $150,000 during the year ended December 31, 2014. At December 31, 2014, we expect to recognize $300,000 of the remaining $743,750 WMD deferred revenue during the next twelve months and accordingly, we have classified the $300,000 as a current liability on our consolidated balance sheets.
	On December 28, 2014, we entered into a royalty and consulting services agreement with FoxBarry Farms, LLC (“FoxBarry”) whereby we received a $200,000 prepaid royalty payment from FoxBarry. We will recognize deferred royalty revenue based on actual applicable sales as defined in the agreement. During the year ended December 31, 2014, we did not recognize any deferred revenue related to this agreement. We have classified the $200,000 as a current liability on our consolidated balance sheets as we expect to recognize this amount during the next twelve months.

NOTES_PAYABLE

NOTES PAYABLE	12 Months Ended
	Dec. 31, 2014
NOTES PAYABLE [Abstract]
NOTES PAYABLE	NOTE 13 – NOTES PAYABLE
	Our notes payable consist of:
		December 31,
		2014		2013
	Note payable - WeedMD	$	175,000	$	—
	Note payable – unrelated third party		600,000		—
	Total notes payable	$	775,000	$	—
	On July 7, 2014, we issued a $175,000, unsecured, demand promissory note bearing interest at 5% to WeedMD for cash used in our business development activities. Interest expense during the year ended December 31, 2014, applicable to this note was $4,267 and accrued interest payable in that amount is included in accrued expenses on our consolidated balance sheets.
	On December 18, 2014, we issued a $600,000 unsecured promissory note bearing interest at 12% to an unrelated third party. The principal and accrued interest are due on the earlier of December 17, 2015, or upon the closing of certain capital raising transactions as described in the note. The default rate of interest under the note is 18%. Debt issuance costs of $13,500 were immediately recognized as interest expense as we expect to close on a capital raising transaction in early 2015.  Interest expense during the year ended December 31, 2014, applicable to this note was $2,565 and accrued interest payable in that amount is included in accrued expenses on our consolidated balance sheets.

CONVERTIBLE_NOTE_PAYABLE

CONVERTIBLE NOTE PAYABLE	12 Months Ended
	Dec. 31, 2014
CONVERTIBLE NOTE PAYABLE [Abstract]
CONVERTIBLE NOTE PAYABLE	NOTE 14 – CONVERTIBLE NOTE PAYABLE
	On August 13, 2014, we entered into a Securities Purchase Agreement with Typenex Co-Investment, LLC ("Typenex"), for the sale of a 10% convertible promissory note (the “Note”) in the principal amount of $1,657,500 (the “Closing Amount”) convertible into shares of our common stock. The Note had an original issue discount (“OID”) of $150,000. Typenex retained $7,500 of the Closing Amount for due diligence and legal bills related to the transaction and paid $25,000 on our behalf to a third party for brokerage fees (together, the “Fees”). The financing closed on August 13, 2014 (the “Closing Date”). The Note was secured by all of our assets.
	The Note's interest rate was 10% per annum. All interest and principal was required to be paid twenty-five months after the date of the first borrowing under the Note (the “Maturity Date”). The outstanding balance on the Note was convertible into our common stock, at Typenex's option, at $3.00 per share (the “Optional Conversion”).
	The Note also contained repayment requirements beginning six months after the first borrowing under the Note. The repayment requirements gave us the option of making periodic repayments in cash or with shares of our common stock at a price discounted to market in accordance with the terms of the Note.
	In addition, we issued to Typenex warrants (the “Warrants”) to purchase 997,692 shares of our common stock, subject to adjustment in the event of a cashless exercise, as defined in the Warrant. Warrants for 170,044 shares were immediately exercisable with the remainder only becoming exercisable, in five tranches, if and when the Investor Notes (see Note 9 above) are paid. The Warrants are exercisable at $3.00 per share (the “Exercise Price”) until August 31, 2017, on a cash or cashless basis. If we, at any time while the Warrants are outstanding, sell or issue our common stock or securities convertible into or exercisable for shares of our common stock, including common stock issued under the Note, at an effective price per share less than the Exercise Price, then, subject to a few exceptions set forth in the Warrant, the Exercise Price will be reduced to such lower price provided that the number of shares of common stock issuable under the Warrant may not exceed a number of shares equal to three times the number of shares of common stock issuable under the Warrants as of the Closing Date.
	On August 15, 2014, we received net cash proceeds from our initial borrowing under the Note of $225,000 as follows: total initial borrowing of $282,500 less the $32,500 of Fees and OID applicable to the initial borrowing of $25,000. We expensed the Fees immediately as interest expense as the initial borrowing and all subsequent tranches were immediately convertible into our common stock by the lender.
	With regards to our $282,500 initial borrowing, on August 15, 2014, we recorded the $25,000 of OID plus the $118,373 fair value of the first Warrant issued, plus $139,127 of the $151,937 fair value of the initial borrowing conversion feature, or, in total, $282,500, as debt discount and recorded the excess, $12,810, as loss on origination of derivative liability in our consolidated statements of operations. We were amortizing the $282,500 debt discount associated with the initial borrowing on a straight line basis, which approximates the effective interest method, over the nine month repayment term of the initial borrowing.
	With regards to the remaining $1,375,000 owed under the Note, we recorded the remaining $125,000 of OID as debt discount. We were amortizing the $125,000 debt discount on a straight line basis, which approximates the effective interest method, over the twenty-five month term of the Note. We also recorded the $576,152 fair value of the Warrants for the purchase of 827,648 of our shares of common stock as debt discount. Debt discount amortization relating to these warrants would be recognized on a straight line basis over the term of each future borrowing under the Note.
	On December 29, 2014, we paid off the Note and accrued interest thereon and we repurchased and cancelled Warrants for the purchase of 827,648 of our shares of common stock held by Typenex. Principal and interest owed to us under the Investor Notes were offset against the principal and interest we owed to Typenex by us under the Note and we paid Typenex $381,714 in cash. We removed the assets and liabilities, including the derivative liability related to the Note and interest payable conversion features, from our consolidated balance sheets and reduced our common stock balance by the amount previously assigned to the Warrants underlying 827,648 shares of our common stock and recorded a loss on extinguishment of debt as follows:
	Convertible note payable	$	1,657,500
	Less: unamortized discount		(822,250	)
	Accrued interest payable		63,326
	Derivative liability		161,158
	Warrants repurchased		576,152
	Less: investor notes receivable		(1,250,000	)
	Less: accrued interest receivable		(37,807	)
	Less: cash paid		(381,714	)
	Loss on extinguishment of debt	$	33,635
	During the year ended December 31, 2014, we recognized $161,402 of debt discount amortization and interest expense totaling $63,326 applicable to this Note.
	The fair value of the conversion feature applicable to accrued interest was $15,320 and this amount was recorded as interest expense and an increase to our derivative liability in our consolidated financial statements.

NOTES_PAYABLE_RELATED_PARTIES

NOTES PAYABLE, RELATED PARTIES	12 Months Ended
	Dec. 31, 2014
NOTES PAYABLE, RELATED PARTIES [Abstract]
NOTES PAYABLE, RELATED PARTIES	NOTE 15 – NOTES PAYABLE, RELATED PARTIES
	In December 2011, we entered into a Revolving Promissory Note (the “Revolving Note”) with Ms. Stoppenhagen, our former President and director. Under the terms of the Revolving Note, Ms. Stoppenhagen agreed to advance us, from time to time and at our request, amounts up to an aggregate of $100,000 until December 31, 2013, with all advances to be paid on or before December 31, 2013, and interest accruing from the date of any advances on any principal amount withdrawn, and on unpaid interest thereon, at the rate of six percent (6%) per annum, compounded annually. As of December 31, 2014 and 2013, nothing was owed under the Revolving Note.
	On September 30, 2013, we issued a Convertible Note (the "Convertible Note") for $50,000 to NYX Capital Advisors, Inc. (“NYX”), an entity owned by Ms. Stoppenhagen's husband, in connection with $50,000 cash paid by NYX.  The Convertible Note bears no interest and was convertible at any time, at the option of the holder, into 10,000,000 shares of our common stock at $0.005 per share.  The Convertible Note was converted into our common shares on February 24, 2014.

STOCKHOLDERS_DEFICIT_EQUITY

STOCKHOLDERS' (DEFICIT) EQUITY	12 Months Ended
	Dec. 31, 2014
STOCKHOLDERS' (DEFICIT) EQUITY [Abstract]
STOCKHOLDERS' (DEFICIT) EQUITY	NOTE 16 – STOCKHOLDERS' (DEFICIT) EQUITY
	Change of control
	On February 27, 2014, NYX and Mr. Paul Enright, our former President, entered into a Stock Purchase Agreement, pursuant to which NYX sold to Mr. Enright an aggregate of 40,000,000 shares of our common stock, representing approximately 87% of our issued and outstanding shares as of that date.
	On March 26, 2014, we cancelled 41,690,000 previously outstanding shares of our common stock and issued 38,690,000 shares to Messrs. Blackmon, Ruby and Verzura, representing approximately 89% of our issued and outstanding shares as of that date.
	Stock split
	On March 21, 2014, we effected a four-for-one stock split of our common stock in the form of a stock dividend of three shares of common stock for each share of common stock outstanding to stockholders of record on March 19, 2014.
	Equity offering
	On March 26, 2014, we sold 600,000 Units for a total amount of $900,000 to 45 accredited investors. Each Unit consisted of one share of our common stock, two A Warrants and three B Warrants. Each A Warrant entitles the holder to purchase one share of our common stock at a price of $7.50 per share during the two year period commencing April 1, 2014, and the A Warrants are callable once our common stock has traded at a price of at least $15.00 for 20 consecutive trading days.  Each B Warrant entitles the holder to purchase one share of our common stock at a price of $15.00 per share during the three year period commencing April 1, 2014, and the B Warrants are callable once our common stock has traded at a price of at least $22.00 for 20 consecutive trading days.
	Change in Authorized Share Capital
	Effective May 2, 2014, we increased the authorized number of our preferred shares from five million to ten million and the authorized number of our common shares from 50 million to 100 million. At the same time we also changed the par value of both our preferred and common stock from $0.001 per share to no par value per share.
	Common Stock Issued For Services
	On August 14, 2014, we issued 10,000 shares of common stock valued at $9,200, based on the previous trading day's closing price, as consideration for marketing services. The $9,200 was recorded as share-based compensation expense and is included in included in sales and marketing expense in our consolidated statements of operations.
	On August 15, 2014, we issued 20,000 shares of common stock valued at $24,800, based on the previous trading day's closing price, as consideration for consulting services. The $24,800 was recorded as share-based compensation expense and is included in included in general and administrative expenses in our consolidated statements of operations.
	On August 25, 2014, we committed to issued 40,000 shares of common stock valued at $88,000, based on the previous trading day's closing price, as consideration for a 50% ownership interest in CRD. The $88,000 is included in included in equity method investments on our consolidated balance sheets. The $88,000 of common stock is included in common stock yet to be issued on our consolidated balance sheets.
	On September 17, 2014, we issued 150,000 shares of common stock valued at $162,000, based on the previous trading day's closing price, as consideration for prepaid investor relations services. The $162,000 is being amortized on a straight-line basis over the 12 month term of the investor relations service agreement. During the year ended December 31, 2014, we recorded $40,500 of amortization as share-based compensation expense and included this in general and administrative expenses in our consolidated statements of operations. The remaining $121,500 as at December 31, 2014, is included in prepaid expenses on our consolidated balance sheets.
	On October 17, 2014, we issued 100,000 shares of common stock valued at $40,000, based on the previous trading day's closing price, as consideration for prepaid product distribution fees. The $40,000 is being amortized on a straight-line basis over the ten year term of the licensing and distribution agreement. During the year ended December 31, 2014, we recorded $1,000 of amortization as share-based compensation expense and included this in cost of revenues in our consolidated statements of operations. The remaining $39,000 as at December 31, 2014, is included in prepaid expenses on our consolidated balance sheets.
	On October 24, 2014, we issued 20,000 shares of common stock valued at $24,000, based on the previous trading day's closing price, as consideration for consulting services. The $24,000 was recorded as share-based compensation expense and is included in included in general and administrative expenses in our consolidated statements of operations.
	On December 1, 2014, we issued 30,000 shares of common stock valued at $19,500, based on the previous trading day's closing price, as consideration for prepaid accounting fees. The $19,500 is being recognized as share-based compensation expense as services are rendered. During the year ended December 31, 2014, we recorded $8,921 of share-based compensation expense and included this in general and administrative expenses in our consolidated statements of operations. The remaining $10,579 as at December 31, 2014, is included in prepaid expenses on our consolidated balance sheets.
	On December 30, 2014, we issued 20,000 shares of common stock valued at $13,800, based on the previous trading day's closing price, as consideration for consulting services. The $13,800 was recorded as share-based compensation expense and is included in included in general and administrative expenses in our consolidated statements of operations.
	Warrants:
	The following table summarizes our share warrants outstanding as of December 31, 2014 and 2013:
		Year Ended December 31, 2014
		Number of			Weighted		Weighted
		Shares
					Average		Average
					Remaining		Exercise
							Price
					Life (years)
	Warrants outstanding, beginning of period		—			—	$	—
	Issued		3,997,692			—		9.75
	Exercised		—			—		—
	Repurchased and cancelled		(827,648	)		—		3
	Expired		—			—		—
	Warrants outstanding, end of period		3,170,044			1.3	$	11.52
	Warrants exercisable, December 31, 2014		3,170,044			1.3	$	11.52
	As described in Note 14 above, on August 13, 2014, we issued Typenex warrants to purchase 997,692 of our common shares and recorded the $694,525 fair value of these warrants as an increase to common stock on our consolidated balance sheets. On December 29, 2014, we repurchased 827,648 of these warrants, cancelled them and recorded a $576,152 decrease in common stock.
	The warrants were recorded at approximately $0.70 per warrant utilizing the Black Scholes option pricing model and the following assumptions on the date of valuation:
	Stock price	$	1.03
	Exercise price	$	3
	Risk free interest rate		0.88	%
	Expected term (years)		3.05
	Expected volatility		146	%
	Expected dividends		0	%
	2004 Equity Incentive Plan
	On November 20, 2014, our board of directors approved our 2014 Stock Incentive Plan (the “Plan”). The Plan provides officers, directors, selected employees and outside consultants an opportunity to acquire or increase a direct ownership interest in our operations and future success. Our board of directors currently administers the Plan and makes all decisions concerning which officers, directors, employees and other persons are granted awards, how many to grant to each recipient, when awards are granted, the terms and conditions applicable to awards, how the Plan should be interpreted, whether to amend or terminate the Plan and whether to delegate administration of the Plan to a committee. A maximum of 4,000,000 common shares are subject to the Plan. The Plan provides for the grant of stock options, stock awards, restricted stock units and stock appreciation rights. Stock options may be non-qualified stock options or incentive stock options except that stock options granted to outside directors, consultants or advisers providing services to us shall in all cases be non-qualified stock options. The Plan will terminate on November 20, 2024, unless the administrator terminates the Plan earlier. As of December 31, 2014, 4,000,000 common shares were available for issue under the Plan.

COMMITMENTS_AND_CONTINGENCIES

COMMITMENTS AND CONTINGENCIES	12 Months Ended
	Dec. 31, 2014
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	NOTE 17 –COMMITMENTS AND CONTINGENCIES
	Contractual Obligations and Commercial Commitments
	On May 6, 2014, we entered into a consultancy agreement with two third party consultants that has a six month term which can be renewed and/or extended by mutual agreement; currently, the renewal of the agreement is under negotiations. The agreement provides for a $50,000 payment at signing, which has been paid, and for three more $50,000 payments and the issuance of 100,000 shares of our common stock upon the achievement of certain goals as set forth in appendix II of the agreement. During the year ended December 31, 2014, we recognized $160,000 of the $200,000 cash payment obligations as research and development expenses in our consolidated statements of operations. At December 31, 2014, $110,000 is included in accrued expenses on our consolidated balance sheet. The value of the 100,000 shares will be recognized upon achievement of the goals, currently anticipated to be during 2015.
	Legal Proceedings
	We were not subject to any legal proceedings during the three and nine months ended December 31, 2014, and, to the best of our knowledge, no legal proceedings are pending or threatened.

INCOME_TAXES

INCOME TAXES	12 Months Ended
	Dec. 31, 2014
INCOME TAXES [Abstract]
INCOME TAXES	NOTE 18 – INCOME TAXES
	The Internal Revenue Code (“IRC”) allows net operating losses (“NOL's”) to be carried forward and applied against future profits for a period of twenty years. The change of ownership following our merger with MySkin may limit our ability to utilize these NOLs under the terms of IRC Section 381.
	We did not provide any current or deferred federal income tax provision or benefit for any of the periods presented in our consolidated financial statements because we have experienced losses since our inception. When it is more likely than not, that a tax asset cannot be realized through future income, we must record an allowance against any potential future tax benefit. We provided a full valuation allowance against our net deferred tax assets, consisting of net operating loss carry forwards, because we determined that it is more likely than not that we will not earn income sufficient to realize the deferred tax assets during the carry forward periods.
	We have not taken a tax position that, if challenged, would have a material effect on our consolidated financial statements for the years ended December 31, 2014 and 2013, as defined under ASC 740. We did not recognize any adjustment to our liability for uncertain tax position and therefore did not record any adjustment to the beginning balance of our accumulated deficit on our consolidated balance sheets.
	Our provision for income taxes differs from the amount computed by applying the statutory federal income tax rate to income before provision for income taxes. The sources and tax effects of the differences for the periods presented are as follows:
		Years Ended December 31,
		2014				2013
	Income tax provision at the federal statutory rate		39	%		39	%
	Effect of operating losses		(39	%)		(39	%)
			—	%		—	%
	Changes in our cumulative net deferred tax assets consist of the following:
		December 31,
		2014			2013
	Net loss carry forward	$	2,207,303		$	156,603
	Valuation allowance		(2,207,303	)		(11,301,282	)
		$	—		$	—
	A reconciliation of our income taxes computed at the statutory rate is as follows:
		Years Ended December 31,
		2014			2013
	Tax at statutory rate	$	799,773		$	1,234
	Valuation allowance		(799,773	)		(1,234	)
		$	—		$	—

RELATED_PARTY_TRANSACTIONS

RELATED PARTY TRANSACTIONS	12 Months Ended
	Dec. 31, 2014
RELATED PARTY TRANSACTIONS [Abstract]
RELATED PARTY TRANSACTIONS	NOTE 20 –RELATED PARTY TRANSACTIONS
	Messrs. Blackmon and Verzura have made loans to or equity investments in one of our customers and are currently in the process of divesting those interests. As Messrs. Blackmon and Verzura may have significant influence on management or operating polices of the customer, we have classified sales to this customer as revenues, affiliate, in our consolidated statements of operations and accounts receivable from this customer as due from related parties on our consolidated balance sheets.
	During the year ended December 31, 2014, we made certain payments on behalf of Lone Mountain during the organizational phase of this venture and have classified these payments as due from related parties on our consolidated balance sheets.
	Amounts due from related parties consist of:
		December 31,
		2014		2013
	Affiliated customer	$	3,112	$	—
	Lone Mountain		40,900		—
	Due from MTA		—		8,862
	Total due from related parties	$	44,012	$	8,862

DISCONTINUED_OPERATIONS

DISCONTINUED OPERATIONS	12 Months Ended
	Dec. 31, 2014
DISCONTINUED OPERATIONS [Abstract]
DISCONTINUED OPERATIONS	NOTE 21 –DISCONTINUED OPERATIONS
	On March 31, 2014, we sold all right, title and interest in the tangible and intangible assets, trademarks, customer lists, intellectual property and rights, which we owned and were related to the advanced skin care business. The assets were sold to MySkin Services, Inc. (“MTA”), a business partly owned by Ms. Stoppenhagen in exchange for a $15,000 payable we owed to Ms. Stoppenhagen and/or MTA.  In addition, MTA assumed all costs associated with these assets starting on March 31, 2014.  See Note 1 for further detail on our change in operations.
	The following details our loss from discontinued operations:
		Years Ended December 31,
		2014			2013
	Revenues	$	20,684		$	105,662
	Operating expenses:
	Selling, general and administrative		63,872			57,146
	Depreciation		—			18,019
	Loss on disposal of assets		15,704			—
	Total operating expenses		79,576			75,165
	Income (loss) from discontinued operations, before income taxes		(58,892	)		30,496
	Provision for income taxes		—			—
	Income (loss) from discontinued operations, net of income taxes	$	(58,892	)	$	30,496
	Our assets held for sale consist of the following and are included in assets of discontinued operations on our consolidated balance sheets:
		December 31,
		2014			2013
	Equipment	$	—		$	17,616

SUBSEQUENT_EVENTS

SUBSEQUENT EVENTS	12 Months Ended
	Dec. 31, 2014
SUBSEQUENT EVENTS [Abstract]
SUBSEQUENT EVENTS	NOTE 22 – SUBSEQUENT EVENTS
	On January 9, 2015, we awarded 200,000 stock options to each of Messrs. Blackmon, Verzura and Ruby under our 2014 Stock Incentive Plan. The options were fully vested at the time of grant and gave the option holder the right to purchase shares of our common stock at $0.70 per share during the ten year term of the option.
	We calculated the fair value of each option to be approximately $0.70 per option utilizing the Black Scholes option pricing model and the following assumptions on the date of valuation:
	Stock price	$	0.7
	Exercise price	$	0.7
	Risk free interest rate		1.98	%
	Expected term (years)		10
	Expected volatility		173	%
	Expected dividends		0	%
	On February 10, 2015, we issued 621,000 shares of our common stock valued at $987,390 based on the previous day's closing price, to Typenex in exchange for the remaining outstanding Warrant to purchase 170,044 of our common shares.
	On March 2, 2015, we issued 30,000 shares of our common stock valued at $42,600 based on the previous day's closing price, in exchange for services.
	In accordance with ASC 855-10 we have analyzed its operations subsequent to December 31, 2014, to the date these consolidated financial statements were issued, and has determined that, other that as disclosed above, we do not have any material subsequent events to disclose in these consolidated financial statements.

SUMMARY_OF_SIGNIFICANT_ACCOUNT1

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policy)	12 Months Ended
	Dec. 31, 2014
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES [Abstract]
Principles of Consolidation	Principles of Consolidation - Our consolidated financial statements include our accounts and the accounts of our wholly-owned subsidiary UC Nevada L.L.C. All intercompany accounts and transactions have been eliminated. Our consolidated financial statements are stated in United States dollars and have been prepared in accordance with accounting principles generally accepted in the United States (“U.S. GAAP”).
Use of Estimates	Use of Estimates - The preparation of our consolidated financial statements in conformity with U.S. GAAP requires us to make estimates, assumptions and judgments that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities as of the date of our consolidated financial statements and the reported amounts of revenues expenses during the periods presented.
	We make our estimate of the ultimate outcome for these items based on historical trends and other information available when our consolidated financial statements are prepared. We recognize changes in estimates in accordance with the accounting rules for the estimate, which is typically in the period when new information becomes available. We believe that our significant estimates, assumptions and judgments are reasonable, based upon information available at the time they were made. Our actual results could differ from these estimates, making it possible that a change in these estimates could occur in the near term.
Financial Instruments	Financial Instruments – We have adopted Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) 825, Financial Instruments, which requires disclosures of information about the fair value of certain financial instruments for which it is practicable to estimate that value. For purposes of this disclosure, the fair value of a financial instrument is the amount at which the instrument could be exchanged in a current transaction between willing parties, other than in a forced sale or liquidation.
	The carrying amounts of our short-term financial instruments, including accounts receivable, prepaid expenses, accounts payable, accrued expenses and deferred revenue approximates fair value due to the relatively short period to maturity for these instruments. Investments in non-marketable equity securities are carried at cost. The carrying amount of our notes payable at December 31, 2014, approximates their fair values based on our incremental borrowing rates.
Cash and Cash Equivalents	Cash and Cash Equivalents - We consider investments with original maturities of 90 days or less to be cash equivalents. We do not have cash equivalents as of December 31, 2014 and 2013.
Accounts Receivable	Accounts Receivable – Our accounts receivable consists primarily of trade accounts arising in the normal course of business. No interest is charged on past due accounts. Accounts for which no payments have been received after 30 days are considered delinquent and customary collection efforts are initiated. Accounts receivable are carried at original invoice amount less a reserve made for doubtful accounts based on a review of all outstanding amounts on a monthly basis.
	We determine our allowance for doubtful accounts by regularly evaluating individual customer receivables and considering the customer's financial condition and credit history, and current economic conditions. Based on our analysis, no allowance for doubtful accounts was necessary as of December 31, 2014 and 2013.
Inventory	Inventory - Inventory is valued at the lower of cost or market. Cost is determined using standard costs, which approximates the first-in, first-out method.
Property and Equipment	Property and Equipment –Our property and equipment are recorded at cost. Maintenance and repairs are expensed as incurred. Depreciation is computed using the straight-line method over an estimated useful life of three to five years. Assets acquired under capital leases are depreciated over the lesser of the useful life of the asset or the lease term. At the time of retirement or other disposition of property and equipment, the cost and accumulated depreciation are removed from our accounts and any resulting gain or loss is reflected in our consolidated statements of operations.
Intangible Assets	Intangible Assets – Our intangible assets, consisting of trademark, design mark and provisional patent applications are recorded at cost, and once approved, are amortized using the straight-line method over an estimated useful life of 10 to 20 years.
Investments in Non-Marketable Equity Securities	Investments in Non-Marketable Equity Securities – Our investments in non-marketable equity securities are carried at cost, less write-down-for-impairments, and are adjusted for impairment based on methodologies, including the valuation achieved in the most recent private placement by the investee, an assessment of the impact of general private equity market conditions, and discounted projected future cash flows. Investments in non-marketable equity securities that expire in less than 12 months, for example stock options or warrants, are classified as current assets; otherwise, we classify investments in non-marketable equity securities as other noncurrent assets.
Long-Lived Assets	Long-Lived Assets – Our intangible assets and other long-lived assets are subject to an impairment test if there is an indicator of impairment. The carrying value and ultimate realization of these assets is dependent upon our estimates of future earnings and benefits that we expect to generate from their use. If our expectations of future results and cash flows are significantly diminished, intangible assets and other long-lived assets may be impaired and the resulting charge to operations may be material. When we determine that the carrying value of intangibles or other long-lived assets may not be recoverable based upon the existence of one or more indicators of impairment, we use the projected undiscounted cash flow method to determine whether an impairment exists, and then measure the impairment using discounted cash flows.
Equity Method Investments	Equity Method Investments – Our investments in entities representing ownership of at least 20% but less than 50%, where we exercise significant influence, are accounted for under the equity method.
Deferred Revenue	Deferred Revenue - We defer revenue for which product or service has not yet been delivered or is subject to refund until such time that we and our customer jointly determine that the product or service has been delivered or no refund will be required.
Revenue Recognition	Revenue Recognition - We recognize revenue in accordance with ASC 605, Revenue Recognition, which requires that four basic criteria must be met before revenue can be recognized: (1) persuasive evidence of an arrangement exists; (2) delivery has occurred; (3) the selling price is fixed and determinable; and (4) collectability is reasonably assured. Determination of criteria (3) and (4) are based on our management's judgments regarding the fixed nature of the selling prices of the products and services delivered and the collectability of those amounts.
	Revenue for services with a payment in form of stock, warrants or other financial assets is recognized when the services are performed. The value of revenue is measured using the Black-Scholes model for warrants.
Cost of Revenues	Cost of Revenues - Our cost of revenues consists primarily of costs associated with the production and delivery of our products and services. These include expenses related to the production, packaging and labeling of our Prana medicinals products and consulting expense related to our advisory services.
Advertising Costs	Advertising Costs - All advertising costs are expensed as incurred.
Research and Development Expenses	Research and Development Expenses - Research and development (“R&D”) costs are charged to expense as incurred. Our R&D costs include, but are not limited to, consulting service fees and materials and supplies used in the development of our proprietary products and services.
Selling, General and Administrative Expenses	Selling, General and Administrative Expenses - Selling, general and administrative expenses consist primarily of personnel-related costs, rent, corporate costs, fees for professional and consulting services, advertising costs, and other costs of administration such as marketing, human resources, finance and administrative roles.
Stock-Based Compensation	Stock-Based Compensation - We periodically issue shares of our common stock to non-employees in non-capital raising transactions for fees and services. We account for stock issued to non-employees in accordance with ASC 505, Equity, whereas the value of the stock compensation is based upon the measurement date as determined at either (a) the date at which a performance commitment is reached, or (b) at the date at which the necessary performance to earn the equity instruments is complete.
	We account for stock option grants issued and vesting to employees based on ASC 718, Compensation – Stock Compensation, whereas the award is measured at its fair value at the date of grant and is amortized ratably over the vesting period. Accounting for stock-based compensation to employees requires the measurement and recognition of compensation expense for all share-based payment awards made to employees based on estimated fair values. We estimate the fair value of all stock option awards on the date of grant using the Black-Scholes-Merton pricing model, which is affected by our stock price, as well as assumptions regarding a number of complex and subjective variables. These variables include our expected stock price volatility over the term of the awards, actual and projected employee option exercise behaviors, risk free interest rates and expected dividends. We also estimate forfeitures at the time of grant and revise those estimates in subsequent periods if actual forfeitures differ from our estimates.
Income Taxes	Income Taxes - Income taxes are recorded using the asset and liability method. Under the asset and liability method, tax assets and liabilities are recognized for the tax consequences attributable to differences between financial statement carrying amounts of existing assets and liabilities and their respective tax bases. Future tax assets and liabilities are measured using the enacted tax rates expected to apply when the asset is realized or the liability settled. The effect on future tax assets and liabilities of a change in tax rates is recognized in income in the period that enactment occurs. To the extent that we do not consider it more likely than not that a future tax asset will be recovered, we will provide a valuation allowance against the excess.
	We follow the provisions of ASC 740, Income Taxes. As a result of the ASC 740, we make a comprehensive review of our portfolio of tax positions in accordance with recognition standards established by ASC 740. As a result of the implementation of ASC 740, we recognized no material adjustments to liabilities or stockholders' (deficit) equity.
	When tax returns are filed, it is highly certain that some positions taken would be sustained upon examination by the taxing authorities, while others are subject to uncertainty about the merits of the position taken or the amount of the position that would be ultimately sustained. The benefit of a tax position is recognized in our consolidated financial statements in the period during which, based on all available evidence, we believe it is more likely than not that the position will be sustained upon examination, including the resolution of appeals or litigation processes, if any. Tax positions taken are not offset or aggregated with other positions. Tax positions that meet the more-likely-than-not recognition threshold are measured as the largest amount of tax benefit that is more than 50 percent likely of being realized upon settlement with the applicable taxing authority. The portion of the benefits associated with tax positions taken that exceeds the amount measured as described above is reflected as a liability for unrecognized tax benefits in the accompanying consolidated balance sheets along with any associated interest and penalties that would be payable to the taxing authorities upon examination.
	Interest and penalties associated with unrecognized tax benefits, if any, are classified as interest expense and penalties and are included in selling, general and administrative expenses in our consolidated statements of operations.
Commitments and Contingencies	Commitments and Contingencies - Certain conditions may exist as of the date our consolidated financial statements are issued, which may result in a loss but which will only be resolved when one or more future events occur or fail to occur.  We assess such contingent liabilities, and such assessment inherently involves an exercise of judgment.  In assessing loss contingencies related to legal proceedings that are pending against us or unasserted claims that may result in such proceedings, we evaluate the perceived merits of the legal proceedings or unasserted claims as well as the perceived merits of the amount of relief sought or expected to be sought therein.
	If the assessment of a contingency indicates that it is probable that a material loss has been incurred and the amount of the liability can be estimated, then the estimated liability would be accrued in our consolidated financial statements.  If the assessment indicates that a potentially material loss contingency is not probable, but is reasonably possible, or is probable but cannot be estimated, then the nature of the contingent liability, together with an estimate of the range of possible loss if determinable and material, would be disclosed.
	Loss contingencies considered remote are generally not disclosed unless they involve guarantees, in which case the nature of the guarantee would be disclosed.
Net Income (Loss) Per Share	Net Income (Loss) Per Share - We compute net income (loss) per share in accordance with ASC 260, Earnings per Share. Under the provisions of ASC 260, basic net income (loss) per share includes no dilution and is computed by dividing the net income (loss) available to common stockholders for the period by the weighted average number of shares of common stock outstanding during the period. Diluted net income (loss) per share takes into consideration shares of common stock outstanding (computed under basic net income (loss) per share) and potentially dilutive securities that are not anti-dilutive.
	Potentially dilutive securities outlined in the table below have been excluded from the computation of diluted net loss per share, because the effect of their inclusion would have been anti-dilutive.
		Years Ended December 31,
		2014			2013
	Warrants to purchase common stock		3,170,044			—
Other Comprehensive Income (Loss)	Other Comprehensive Income (Loss) – We report as other comprehensive income (loss) those revenues, gains and losses not included in the determination of net income.  During the years ended December 31, 2014 and 2013, we did not have any gains and losses resulting from activities or transactions that resulted in comprehensive income or loss.
Segment Reporting	Segment Reporting – UCANN operates as one segment.
Concentration of Credit Risk	Concentration of Credit Risk - Financial instruments that potentially subject us to credit risk consist of cash. We maintain our cash with high credit quality financial institutions; at times, such balances with any one financial institution may not be insured by the FDIC.
	The following tables show significant concentrations in our revenues and accounts receivable for the periods indicated:
	Percentage of Revenue:
		Years Ended December 31,
		2014			2013
	Customer A		80	%		—	%
	Percentage of Accounts Receivable:
		Years Ended December 31,
		2014			2013
	Customer B		46	%		—	%
	Customer C		33	%		—	%
	Customer D		21	%		—	%
Recently Issued Accounting Pronouncements	Recently Issued Accounting Pronouncements - From time to time, the FASB or other standards setting bodies issue new accounting pronouncements. Updates to the FASB ASCs are communicated through issuance of an Accounting Standards Update ("ASU"). Unless otherwise discussed, we believe that the impact of recently issued guidance, whether adopted or to be adopted in the future, is not expected to have a material impact on our consolidated financial statements upon adoption.
	In May 2014 the FASB issued guidance on revenue from contracts with customers, which implements a five step process of how an entity should recognize revenue in order to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. This guidance will be effective at the beginning of fiscal year 2018, and early application is not permitted. The standard permits the use of either the retrospective or cumulative effect transition method. We are currently evaluating the impact that the adoption will have on our consolidated financial statements and related disclosures. We have not yet selected a transition method nor have we determined the effect of the standard on our ongoing reporting.

SUMMARY_OF_SIGNIFICANT_ACCOUNT2

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)	12 Months Ended
	Dec. 31, 2014
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES [Abstract]
Schedule of potentially dilutive securities that have been excluded from the computation of diluted net loss per share, because the effect of their inclusion would have been anti-dilutive		Years Ended December 31,
		2014			2013
	Warrants to purchase common stock		3,170,044			—
Schedule of significant concentrations in revenues and accounts receivable	Percentage of Revenue:
		Years Ended December 31,
		2014			2013
	Customer A		80	%		—	%
	Percentage of Accounts Receivable:
		Years Ended December 31,
		2014			2013
	Customer B		46	%		—	%
	Customer C		33	%		—	%
	Customer D		21	%		—	%

INVESTMENTS_IN_NONMARKETABLE_E1

INVESTMENTS IN NON-MARKETABLE EQUITY SECURITIES (Tables)	12 Months Ended
	Dec. 31, 2014
INVESTMENTS IN NON-MARKETABLE EQUITY SECURITIES [Abstract]
Schedule of Fair Value Assumptions Used to Value Warrants	Risk free interest rate	0.6	%
	Expected term (years)	0.5
	Expected volatility	70	%
	Expected dividends	0	%

PREPAID_EXPENSES_Tables

PREPAID EXPENSES (Tables)	12 Months Ended
	Dec. 31, 2014
PREPAID EXPENSES [Abstract]
Schedule of prepaid expenses		December 31,
		2014		2013
	Prepaid investor relations services	$	121,500	$	—
	Other prepaid services and fees		55,900		—
		$	177,400	$	—

EQUIPMENT_Tables

EQUIPMENT (Tables)	12 Months Ended
	Dec. 31, 2014
EQUIPMENT [Abstract]
Schedule of equipment, included in assets of discontinued operations		December 31,
		2014		2013
	Equipment	$	—	$	131,584
	Less accumulated depreciation		—		(113,968	)
		$	—	$	17,616

EQUITY_METHOD_INVESTMENTS_Tabl

EQUITY METHOD INVESTMENTS (Tables)	12 Months Ended
	Dec. 31, 2014
EQUITY METHOD INVESTMENTS [Abstract]
Schedule of equity method investments		December 31,
		2014		2013
	Lone Mountain Partners, LLC – 25% interest	$	50,000	$	—
	Cannabinoid Research & Development Company Limited – 50%		88,000		—
	Total equity method investments	$	138,000	$	—

ACCRUED_EXPENSES_Tables

ACCRUED EXPENSES (Tables)	12 Months Ended
	Dec. 31, 2014
ACCRUED EXPENSES [Abstract]
Schedule of accrued expenses		December 31,
		2014		2013
	Accrued consulting fees	$	110,000	$	—
	Accrued wages and related		433,963		—
	Accrued interest expense		6,832		—
	Total accrued expenses	$	550,795	$	—

FAIR_VALUE_MEASUREMENTS_AND_DE1

FAIR VALUE MEASUREMENTS AND DERIVATIVE LIABILITY (Tables)	12 Months Ended
	Dec. 31, 2014
FAIR VALUE MEASUREMENTS AND DERIVATIVE LIABILITY [Abstract]
Schedule of reconciliation of beginning and ending balances for financial instruments carried at fair value measured on a recurring basis	Derivative liability as of December 31, 2013	$	—
	Additions to derivative liability for convertible debt conversion feature recorded as debt discount		151,937
	Additions to derivative liability for interest payable conversion feature recorded as interest expense		15,320
	Gain on revaluation of derivative liability during the year		(6,099	)
	Settlement of derivative liability on December 29, 2014		(161,158	)
	Derivative liability as of December 31, 2014	$	—
Schedule of key inputs in valuation of embedded conversion features	Risk-free interest rate	0.43% – 0.72%
	Dividend yield	—
	Volatility	146%–172%
	Expected life in years	1.72–2.09
	Exercise price	$3.00

DEFERRED_REVENUE_Tables

DEFERRED REVENUE (Tables)	12 Months Ended
	Dec. 31, 2014
DEFERRED REVENUE.
Schedule of deferred revenue		December 31,
			2014		2013
	Deferred revenue – WeedMD	$	743,750		$	—
	Deferred revenue - FoxBarry		200,000			—
	Less – current portion		(500,000	)		—
	Deferred revenue, net of current portion	$	443,750		$	—

NOTES_PAYABLE_Tables

NOTES PAYABLE (Tables)	12 Months Ended
	Dec. 31, 2014
NOTES PAYABLE [Abstract]
Schedule of notes payable		December 31,
		2014		2013
	Note payable - WeedMD	$	175,000	$	—
	Note payable – unrelated third party		600,000		—
	Total notes payable	$	775,000	$	—

CONVERTIBLE_NOTE_PAYABLE_Table

CONVERTIBLE NOTE PAYABLE (Tables)	12 Months Ended
	Dec. 31, 2014
CONVERTIBLE NOTE PAYABLE [Abstract]
Schedule of recorded loss on extinguishment of debt	Convertible note payable	$	1,657,500
	Less: unamortized discount		(822,250	)
	Accrued interest payable		63,326
	Derivative liability		161,158
	Warrants repurchased		576,152
	Less: investor notes receivable		(1,250,000	)
	Less: accrued interest receivable		(37,807	)
	Less: cash paid		(381,714	)
	Loss on extinguishment of debt	$	33,635

STOCKHOLDERS_DEFICIT_EQUITY_Ta

STOCKHOLDERS' (DEFICIT) EQUITY (Tables)	12 Months Ended
	Dec. 31, 2014
STOCKHOLDERS' (DEFICIT) EQUITY [Abstract]
Summary of share warrants outstanding		Year Ended December 31, 2014
		Number of			Weighted		Weighted
		Shares
					Average		Average
					Remaining		Exercise
							Price
					Life (years)
	Warrants outstanding, beginning of period		—			—	$	—
	Issued		3,997,692			—		9.75
	Exercised		—			—		—
	Repurchased and cancelled		(827,648	)		—		3
	Expired		—			—		—
	Warrants outstanding, end of period		3,170,044			1.3	$	11.52
	Warrants exercisable, December 31, 2014		3,170,044			1.3	$	11.52
Schedule of assumptions on the date of valuation utilizing the Black Scholes option pricing model for fair value of each warrants	Stock price	$	1.03
	Exercise price	$	3
	Risk free interest rate		0.88	%
	Expected term (years)		3.05
	Expected volatility		146	%
	Expected dividends		0	%

INCOME_TAXES_Tables

INCOME TAXES (Tables)	12 Months Ended
	Dec. 31, 2014
INCOME TAXES [Abstract]
Schedule of sources and tax effects of the differences for the periods		Years Ended December 31,
		2014				2013
	Income tax provision at the federal statutory rate		39	%		39	%
	Effect of operating losses		(39	%)		(39	%)
			—	%		—	%
Schedule of changes in cumulative net deferred tax assets		December 31,
		2014			2013
	Net loss carry forward	$	2,207,303		$	156,603
	Valuation allowance		(2,207,303	)		(11,301,282	)
		$	—		$	—
Schedule of reconciliation of income taxes computed at the statutory rate		Years Ended December 31,
		2014			2013
	Tax at statutory rate	$	799,773		$	1,234
	Valuation allowance		(799,773	)		(1,234	)
		$	—		$	—

RELATED_PARTY_TRANSACTIONS_Tab

RELATED PARTY TRANSACTIONS (Tables)	12 Months Ended
	Dec. 31, 2014
RELATED PARTY TRANSACTIONS [Abstract]
Schedule of amounts due from related parties		December 31,
		2014		2013
	Affiliated customer	$	3,112	$	—
	Lone Mountain		40,900		—
	Due from MTA		—		8,862
	Total due from related parties	$	44,012	$	8,862

DISCONTINUED_OPERATIONS_Tables

DISCONTINUED OPERATIONS (Tables)	12 Months Ended
	Dec. 31, 2014
DISCONTINUED OPERATIONS [Abstract]
Schedule of Loss from Discontinued Operations		Years Ended December 31,
		2014			2013
	Revenues	$	20,684		$	105,662
	Operating expenses:
	Selling, general and administrative		63,872			57,146
	Depreciation		—			18,019
	Loss on disposal of assets		15,704			—
	Total operating expenses		79,576			75,165
	Income (loss) from discontinued operations, before income taxes		(58,892	)		30,496
	Provision for income taxes		—			—
	Income (loss) from discontinued operations, net of income taxes	$	(58,892	)	$	30,496

SUBSEQUENT_EVENTS_Tables

SUBSEQUENT EVENTS (Tables)	12 Months Ended
	Dec. 31, 2014
SUBSEQUENT EVENTS [Abstract]
Schedule of assumptions on the date of valuation utilizing the Black Scholes option pricing model for fair value of each option	Stock price	$	0.7
	Exercise price	$	0.7
	Risk free interest rate		1.98	%
	Expected term (years)		10
	Expected volatility		173	%
	Expected dividends		0	%

BUSINESS_ORGANIZATION_AND_NATU1

BUSINESS ORGANIZATION AND NATURE OF OPERATIONS (Details) (USD $)	0 Months Ended	1 Months Ended
	Mar. 19, 2014	Mar. 31, 2014	Dec. 31, 2014	Mar. 26, 2014	Dec. 31, 2013
BUSINESS ORGANIZATION AND NATURE OF OPERATIONS [Abstract]
Stock split ratio	0.25
Amount of payable owed to former officer and director, exchanged for assets sold		$15,000
Number of common shares issued in exchange for certain intellectual property		38,690,000
Total number of common shares previously outstanding, cancelled during period				41,690,000
Common stock, shares outstanding			44,020,000	43,620,000	6,020,000

SUMMARY_OF_SIGNIFICANT_ACCOUNT3

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Narrative) (Details) (USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013
	Item
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES [Abstract]
Cash equivalents
Allowance for doubtful accounts
Number of operating segment	1
Minimum [Member]
Property, Plant and Equipment [Line Items]
Estimated useful lives	3 years
Maximum [Member]
Property, Plant and Equipment [Line Items]
Estimated useful lives	5 years

SUMMARY_OF_SIGNIFICANT_ACCOUNT4

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Intangible Assets) (Details)	12 Months Ended
	Dec. 31, 2014
Minimum [Member]
Intangible Assets [Line Items]
Estimated useful life	10 years
Maximum [Member]
Intangible Assets [Line Items]
Estimated useful life	20 years

SUMMARY_OF_SIGNIFICANT_ACCOUNT5

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Schedule of anti-dilutive securities) (Details) (Warrants to purchase common stock [Member])	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013
Warrants to purchase common stock [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of diluted net loss per share	3,170,044

SUMMARY_OF_SIGNIFICANT_ACCOUNT6

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Schedule of concentration of credit risk) (Details)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013
Revenue [Member] | Customer A [Member]
Concentration Risk [Line Items]
Concentration risk percentage	80.00%
Accounts Receivable [Member] | Customer B [Member]
Concentration Risk [Line Items]
Concentration risk percentage	46.00%
Accounts Receivable [Member] | Customer C [Member]
Concentration Risk [Line Items]
Concentration risk percentage	33.00%
Accounts Receivable [Member] | Customer D [Member]
Concentration Risk [Line Items]
Concentration risk percentage	21.00%

GOING_CONCERN_Details

GOING CONCERN (Details) (USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013
GOING CONCERN [Abstract]
Net loss (income)	$2,468,364	$3,165
Net cash used in operating activities	1,189,057	25,816
Working capital deficit	1,304,209
Accumulated deficit	$2,624,967	$156,603

INVESTMENTS_IN_NONMARKETABLE_E2

INVESTMENTS IN NON-MARKETABLE EQUITY SECURITIES (Narrative) (Details)	12 Months Ended		0 Months Ended		12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013	Dec. 09, 2014	Jun. 09, 2014	Dec. 31, 2014	Dec. 31, 2014	Jun. 30, 2014
	USD ($)	USD ($)	WeedMD RX Inc. (''WMD'') [Member]	WeedMD RX Inc. (''WMD'') [Member]	WeedMD RX Inc. (''WMD'') [Member]	WeedMD RX Inc. (''WMD'') [Member]	WeedMD RX Inc. (''WMD'') [Member]
					USD ($)	CAD	CAD
Schedule of Cost-method Investments [Line Items]
Common shares received in exchange for future consulting services and use of our intellectual property				1,187,500
Warrants received in exchange for future consulting services and use of our intellectual property				3,000,000
Equity investment				4.29%
Exercise price of warrants received to purchase shares							0.5
Common shares, price per share					$0.50	0.5
Investments in non-marketable equity securities	$593,750				$593,750
Warrants, price per warrant					$0.10
Warrants expired			3,000,000
Loss on investment in non-marketable equity securities	$300,000				$300,000

INVESTMENTS_IN_NONMARKETABLE_E3

INVESTMENTS IN NON-MARKETABLE EQUITY SECURITIES (Schedule of Assumptions) (Details) (Cost-method Investments [Member], Warrant [Member], WeedMD RX Inc. (''WMD'') [Member])	12 Months Ended
	Dec. 31, 2014
Cost-method Investments [Member] | Warrant [Member] | WeedMD RX Inc. (''WMD'') [Member]
Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques [Line Items]
Pricing model	Black Scholes
Risk free interest rate	0.60%
Expected term	6 months
Expected volatility	70.00%
Expected dividends	0.00%

PREPAID_EXPENSES_Details

PREPAID EXPENSES (Details) (USD $)	Dec. 31, 2014	Dec. 31, 2013
PREPAID EXPENSES [Abstract]
Prepaid investor relations services	$121,500
Other prepaid services and fees	55,900
Total prepaid expenses	$177,400

EQUIPMENT_Details

EQUIPMENT (Details) (USD $)	Dec. 31, 2014	Dec. 31, 2013
EQUIPMENT [Abstract]
Equipment		$131,584
Less accumulated depreciation and amortization		-113,968
Equipment, net		$17,616

INTANGIBLES_Details

INTANGIBLES (Details)	12 Months Ended
	Dec. 31, 2014
Patents [Member]
Intangibles [Line Items]
Estimated useful life	20 years
Design marks and trademarks [Member]
Intangibles [Line Items]
Estimated useful life	10 years

EQUITY_METHOD_INVESTMENTS_Sche

EQUITY METHOD INVESTMENTS (Schedule of equity method investments) (Details) (USD $)	Dec. 31, 2014	Dec. 31, 2013	Aug. 14, 2014	Aug. 25, 2014	Aug. 15, 2014
Schedule of Equity Method Investments [Line Items]
Equity method investments	$138,000
Lone Mountain [Member]
Schedule of Equity Method Investments [Line Items]
Interest owned (as a percentage)	25.00%		25.00%
Equity method investments	50,000		50,000
Cannabinoid Research And Development Company Limited [Member]
Schedule of Equity Method Investments [Line Items]
Interest owned (as a percentage)	50.00%			50.00%	50.00%
Equity method investments	$88,000			$88,000	$88,000

EQUITY_METHOD_INVESTMENTS_Narr

EQUITY METHOD INVESTMENTS (Narrative) (Details) (USD $)	0 Months Ended
	Aug. 15, 2014	Dec. 31, 2014	Dec. 31, 2013	Aug. 14, 2014	Aug. 25, 2014
Schedule of Equity Method Investments [Line Items]
Equity method investments		$138,000
Lone Mountain [Member]
Schedule of Equity Method Investments [Line Items]
Interest acquired (as a percentage)		25.00%		25.00%
Equity method investments		50,000		50,000
Cannabinoid Research And Development Company Limited [Member]
Schedule of Equity Method Investments [Line Items]
Interest acquired (as a percentage)	50.00%	50.00%			50.00%
Equity method investments	88,000	88,000			88,000
Shares of common stock issuable for acquisition of interest	40,000
Common stock not yet issued		$88,000

NOTES_RECEIVABLE_AND_INTEREST_1

NOTES RECEIVABLE AND INTEREST INCOME (Details) (USD $)	12 Months Ended
	Dec. 31, 2014	Aug. 13, 2014
Accounts, Notes, Loans and Financing Receivable [Line Items]
Convertible note payable	$1,657,500
Notes receivable, face amount	1,250,000
Five unsecured Investor Notes | Typenex Co-Investment, LLC [Member]
Accounts, Notes, Loans and Financing Receivable [Line Items]
Convertible note payable		1,657,500
Notes receivable, face amount		1,250,000
Notes receivable, interest rate (as a percent)		8.00%
Interest income	37,807
Investor Notes | Typenex Co-Investment, LLC [Member]
Accounts, Notes, Loans and Financing Receivable [Line Items]
Notes receivable, face amount		$250,000

ACCRUED_EXPENSES_Details

ACCRUED EXPENSES (Details) (USD $)	Dec. 31, 2014	Dec. 31, 2013
ACCRUED EXPENSES [Abstract]
Accrued consulting fees	$110,000
Accrued wages and related	433,963
Accrued interest expense	6,832
Total accrued expenses	$550,795

FAIR_VALUE_MEASUREMENTS_AND_DE2

FAIR VALUE MEASUREMENTS AND DERIVATIVE LIABILITY (Narrative) (Details) (USD $)	Dec. 31, 2014	Aug. 15, 2014
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Accrued interest payable	$63,326
Convertible Note [Member] | Typenex Co-Investment, LLC [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Debt instrument initial borrowing		282,500
Accrued interest payable	$28,473

FAIR_VALUE_MEASUREMENTS_AND_DE3

FAIR VALUE MEASUREMENTS AND DERIVATIVE LIABILITY (Schedule of reconciliation of beginning and ending balances for financial instruments carried at fair value measured on a recurring basis) (Details) (Derivative instruments related to embedded conversion features [Member], USD $)	12 Months Ended
	Dec. 31, 2014
Reconciliation of beginning and ending balances for financial instruments carried at fair value measured on a recurring basis
Derivative liability at the beginning of the period
Settlement of derivative liability on December 29, 2014	-161,158
Derivative liability at the end of the period
Debt discount [Member]
Reconciliation of beginning and ending balances for financial instruments carried at fair value measured on a recurring basis
Additions to derivative liability recorded in statements of operations	151,937
Interest expense [Member]
Reconciliation of beginning and ending balances for financial instruments carried at fair value measured on a recurring basis
Additions to derivative liability recorded in statements of operations	15,320
Gain on derivative liability [Member]
Reconciliation of beginning and ending balances for financial instruments carried at fair value measured on a recurring basis
Additions to derivative liability recorded in statements of operations	($6,099)

FAIR_VALUE_MEASUREMENTS_AND_DE4

FAIR VALUE MEASUREMENTS AND DERIVATIVE LIABILITY (Schedule of key inputs in valuation of embedded conversion features) (Details) (Recurring basis [Member], Derivative instruments related to embedded conversion features [Member], Level 3 [Member], USD $)	12 Months Ended
	Dec. 31, 2014
Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques [Line Items]
Dividend yield
Exercise price (in dollars per share)	$3
Minimum [Member]
Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques [Line Items]
Risk-free interest rate (as a percent)	0.43%
Volatility (as a percent)	146.00%
Expected life in years	1 year 8 months 19 days
Maximum [Member]
Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques [Line Items]
Risk-free interest rate (as a percent)	0.72%
Volatility (as a percent)	172.00%
Expected life in years	2 years 1 month 2 days

DEFERRED_REVENUE_Details

DEFERRED REVENUE (Details) (USD $)	0 Months Ended	12 Months Ended
	Jun. 09, 2014	Dec. 31, 2014	Dec. 31, 2013
Deferred Revenue Arrangement [Line Items]
Less - current portion		($500,000)
Total equity method investments		443,750
WeedMD [Member]
Deferred Revenue Arrangement [Line Items]
Deferred revenue current and noncurrent		743,750
Less - current portion		300,000
Common shares received in exchange for future consulting services and use of our intellectual property	1,187,500
Warrants received in exchange for future consulting services and use of our intellectual property	3,000,000
Fair value of securities recorded as deferred revenue	893,750
Deferred revenue recognized per month		25,000
Total deferred revenue recognized		150,000
FoxBarry [Member]
Deferred Revenue Arrangement [Line Items]
Deferred revenue current and noncurrent		200,000
Total deferred revenue recognized		$200,000

NOTES_PAYABLE_Schedule_of_Note

NOTES PAYABLE (Schedule of Notes Payble) (Details) (USD $)	Dec. 31, 2014	Dec. 31, 2013
Short-term Debt [Line Items]
Notes payable	$775,000
Note payable [Member] | WeedMD [Member]
Short-term Debt [Line Items]
Notes payable	175,000
Note payable [Member] | Unrelated third party [Member]
Short-term Debt [Line Items]
Notes payable	$600,000

NOTES_PAYABLE_Narrative_Detail

NOTES PAYABLE (Narrative) (Details) (USD $)	0 Months Ended
	Dec. 18, 2014	Dec. 31, 2014	Dec. 31, 2013	Jul. 07, 2014
Short-term Debt [Line Items]
Accrued interest payable		$6,832
Note payable [Member] | WeedMD [Member]
Short-term Debt [Line Items]
Debt instrument, face amount				175,000
Debt instrument, interest rate				5.00%
Accrued interest payable		4,267
Note payable [Member] | Unrelated third party [Member]
Short-term Debt [Line Items]
Debt instrument, face amount	600,000
Debt instrument, interest rate	12.00%
Default rate of interest under the note	18.00%
Debt issuance costs	13,500
Accrued interest payable		$2,565

CONVERTIBLE_NOTE_PAYABLE_Narra

CONVERTIBLE NOTE PAYABLE (Narrative) (Details) (USD $)	12 Months Ended		0 Months Ended
	Dec. 31, 2014	Dec. 31, 2013	Aug. 13, 2014	Aug. 15, 2014	Sep. 30, 2013
			Item
Debt Instrument [Line Items]
Convertible note payable	$1,657,500
Original issue discount	822,250
Net cash proceeds received from initial borrowing		50,000
Loss on origination of derivative liability	6,099
Unamortized debt discount applicable to initial borrowing [Abstract]
Less: loss on origination of derivative	-12,810
Fair value of the Warrant issued recorded as debt discount under remaining borrowing	576,152
Components of convertible debt, net
Debt discount - conversion feature expensed as loss on origination of derivative	-12,810
Debt discount amortization and interest expense	161,402
Repurchased and cancelled (shares)	-827,648
Warrant [Member]
Debt Instrument [Line Items]
Exercise price (in dollars per share)	$0.70
Typenex Co-Investment, LLC [Member] | Warrant [Member]
Debt Instrument [Line Items]
Number of warrants issued to purchase shares of common stock			997,692
Number of shares for which warrant became exercisable			170,044
Number of tranches in which remaining warrants are exercisable into number of shares			5
Frequency of number of shares of common stock issuable under the Warrants			3
Expiration date			31-Aug-17
Convertible Note [Member]
Debt Instrument [Line Items]
Debt instrument, face amount					50,000
Debt instrument, term			25 months
Debt conversion, price per share			3		$0.01
Components of convertible debt, net
Note					50,000
Convertible Note [Member] | Warrant [Member]
Debt Instrument [Line Items]
Exercise price (in dollars per share)			3
Convertible Note [Member] | Typenex Co-Investment, LLC [Member]
Debt Instrument [Line Items]
Debt instrument, interest rate			10.00%
Debt instrument, face amount			1,657,500
Original issue discount			150,000	225,000
Legal expenses			7,500	32,500
Payment of brokerage fees			25,000
Net cash proceeds received from initial borrowing				25,000
Debt instrument initial borrowing				282,500
Loss on origination of derivative liability				12,810
Portion of fair value of initial borrowing conversion feature recorded as debt discount under initial borrowing				139,127
Unamortized debt discount applicable to initial borrowing [Abstract]
Debt discount - Warrant #1	118,373
Debt discount - conversion feature				151,937
Unamortized debt discount - end of period				282,500
Debt Instrument Initial Borrowing Unamortized, Discount	25,000
Debt instrument remaining borrowing				1,375,000
Original issue discount under remaining borrowing				125,000
Fair value of the Warrant issued recorded as debt discount under remaining borrowing				576,152
Total debt discount under remaining borrowing				125,000
Components of convertible debt, net
Note			1,657,500
Debt discount - conversion feature				151,937
Debt discount amortization and interest expense	161,402
Interest expense	63,326
Fair value of the conversion feature applicable to accrued interest	$15,320
Repurchased and cancelled (shares)	827,648

CONVERTIBLE_NOTE_PAYABLE_Sched

CONVERTIBLE NOTE PAYABLE (Schedule of Recorded a Loss on Extinguishment of Debt) (Details) (USD $)	12 Months Ended
	Dec. 31, 2014
CONVERTIBLE NOTE PAYABLE [Abstract]
Convertible note payable	$1,657,500
Less: unamortized discount	-822,250
Accrued interest payable	63,326
Derivative liability	161,158
Warrants repurchased	576,152
Less: investor notes receivable	-1,250,000
Less: accrued interest receivable	-37,807
Less: cash paid	-381,714
Loss on extinguishment of debt	$33,635

NOTES_PAYABLE_RELATED_PARTIES_

NOTES PAYABLE, RELATED PARTIES (Details) (USD $)	1 Months Ended	12 Months Ended	1 Months Ended
	Sep. 30, 2013	Dec. 31, 2014	Dec. 31, 2011	Dec. 31, 2013	Aug. 13, 2014
Related Party Transaction [Line Items]
Convertible note payable, related party				$50,000
Convertible Debt [Member]
Related Party Transaction [Line Items]
Debt instrument, face amount	50,000
Number of common stock shares debt instrument can be converted to	10,000,000
Debt conversion, price per share	$0.01				$3
Debt instrument, conversion date		24-Feb-14
Former President [Member] | Revolving Promissory Note [Member]
Related Party Transaction [Line Items]
Debt instrument, face amount			$100,000
Debt instrument, interest rate			6.00%
Debt instrument, maturity date			31-Dec-13

STOCKHOLDERS_DEFICIT_EQUITY_Ch

STOCKHOLDERS' (DEFICIT) EQUITY (Change of control, Stock split, Equity offering, and Change in Authorized Capital) (Details) (USD $)	1 Months Ended
	Aug. 28, 2014	Mar. 31, 2014	Dec. 31, 2014	2-May-14	1-May-14	Dec. 31, 2013
STOCKHOLDERS' (DEFICIT) EQUITY [Abstract]
Common stock sold under stock purchase agreement, representing approximately 87% of the issued and outstanding shares of the Company	40,000,000
Shares cancelled		41,690,000
Shares issued to Messrs. Blackmon, Ruby and Verzura, representing approximately 89% of issued and outstanding shares		38,690,000
Number of units sold through equity offering		600,000
Proceeds from sale of units		$900,000
Per share price A Warrant holders can purchase each share of the Company's common stock during the two year period commencing April 1, 2014		$7.50
Per share price B Warrant holders can purchase each share of the Company's common stock during the three year period commencing April 1, 2014		$15
Preferred stock, shares authorized			10,000,000	10,000,000	5,000,000	10,000,000
Preferred stock, par value per share					$0.00
Preferred stock, no par value
Common stock, shares authorized			100,000,000	100,000,000	50,000,000	100,000,000
Common stock, par value per share					$0.00
Common stock, no par value

STOCKHOLDERS_DEFICIT_EQUITY_Co

STOCKHOLDERS' (DEFICIT) EQUITY (Common Stock Issued For Services, Warrants and 2004 Equity Incentive Plan) (Details) (USD $)

0 Months Ended

12 Months Ended

0 Months Ended

Dec. 30, 2014

Oct. 24, 2014

Aug. 25, 2014

Aug. 14, 2014

Aug. 15, 2014

Dec. 31, 2014

Dec. 29, 2014

Aug. 13, 2014

Sep. 17, 2014

Oct. 17, 2014

Dec. 01, 2014

Dec. 31, 2013

Nov. 20, 2014

Stockholders Equity [Line Items]

Number of shares of common stock issued for services

20,000

20,000

10,000

20,000

Value of shares of common stock issued for services

$13,800

$24,000

$9,200

$24,800

$305,100

Number of shares of common stock committed to be issued for services

40,000

Value of shares of common stock committed to be issued for services

88,000

Equity method investments

138,000

Warrants issued with convertible debt

694,525

Purchase and cancellation of warrants

-576,152

Number of Shares

Warrants outstanding, beginning of period (in shares)

Issued (in shares)

3,997,692

Exercised (in shares)

Repurchased and cancelled (shares)

-827,648

Expired (in shares)

Warrants outstanding, end of period (in shares)

3,170,044

Warrants exercisable at the end of the period (in shares)

3,170,044

Weighted Average Remaining Life (years)

Warrants outstanding, beginning of period

1 year 3 months 18 days

Warrants exercisable at the end of the period

1 year 3 months 18 days

Warrants outstanding, end of period

1 year 3 months 18 days

Weighted Average Exercise Price

Warrants outstanding, beginning of period (in dollars per share)

Issued (in dollars per share)

$9.75

Exercised (in dollars per share)

Repurchased and cancelled (in dollars per share)

$3

Expired (in dollars per share)

Warrants outstanding, end of period (in dollars per share)

$11.52

Warrants exercisable at the end of the period (in dollars per share)

$11.52

2014 Stock Incentive Plan [Member]

Stockholders Equity [Line Items]

Maximum number of shares to be issued

4,000,000

Number of shares available for issue

4,000,000

Typenex Co Investment Llc [Member] | Warrant [Member]

Stockholders Equity [Line Items]

Number of warrants issued to purchase shares of common stock

997,692

Warrants issued with convertible debt

694,525

Purchase and cancellation of warrants

-576,152

Shares issued on September 17, 2014 [Member]

Stockholders Equity [Line Items]

Number of shares of common stock issued for services

150,000

Value of shares of common stock issued for services

162,000

162,000

Amortization term

12 months

Shares issued on October 17, 2014 [Member]

Stockholders Equity [Line Items]

Number of shares of common stock issued for services

100,000

Value of shares of common stock issued for services

40,000

40,000

Amortization term

10 years

Shares issued on December 1, 2014 [Member]

Stockholders Equity [Line Items]

Number of shares of common stock issued for services

30,000

Value of shares of common stock issued for services

19,500

19,500

Cannabinoid Research And Development Company Limited [Member]

Stockholders Equity [Line Items]

Ownership interest (as a percent)

50.00%

50.00%

50.00%

Equity method investments

88,000

88,000

88,000

Prepaid Expenses and Other Current Assets [Member] | Shares issued on September 17, 2014 [Member]

Stockholders Equity [Line Items]

Value of shares of common stock issued for services

121,500

Prepaid Expenses and Other Current Assets [Member] | Shares issued on October 17, 2014 [Member]

Stockholders Equity [Line Items]

Value of shares of common stock issued for services

39,000

Prepaid Expenses and Other Current Assets [Member] | Shares issued on December 1, 2014 [Member]

Stockholders Equity [Line Items]

Value of shares of common stock issued for services

10,579

Selling and Marketing Expense [Member]

Stockholders Equity [Line Items]

Value of shares of common stock issued for services

9,200

General and Administrative Expense [Member]

Stockholders Equity [Line Items]

Value of shares of common stock issued for services

13,800

24,000

24,800

General and Administrative Expense [Member] | Shares issued on September 17, 2014 [Member]

Stockholders Equity [Line Items]

Value of shares of common stock issued for services

40,500

General and Administrative Expense [Member] | Shares issued on October 17, 2014 [Member]

Stockholders Equity [Line Items]

Value of shares of common stock issued for services

1,000

General and Administrative Expense [Member] | Shares issued on December 1, 2014 [Member]

Stockholders Equity [Line Items]

Value of shares of common stock issued for services

$8,921

STOCKHOLDERS_DEFICIT_EQUITY_Sc

STOCKHOLDERS' (DEFICIT) EQUITY (Schedule of Assumptions on Date of Valuation Utilizing Black Scholes Option Pricing Model for Fair Value of Each Warrants) (Details) (Warrant [Member], USD $)	12 Months Ended
	Dec. 31, 2014
Warrant [Member]
Warrants [Line Items]
Warrants price (on dollars per shares)	$0.70
Stock price (in dollars per share)	$1.03
Exercise price (in dollars per share)	$3
Risk free interest rate (as a percent)	0.88%
Expected term (years)	3 years 18 days
Expected volatility (as a percent)	146.00%
Expected dividends (as a percent)	0.00%

COMMITMENTS_AND_CONTINGENCIES_

COMMITMENTS AND CONTINGENCIES (Details) (USD $)	1 Months Ended	12 Months Ended
	31-May-14	Dec. 31, 2014	Dec. 31, 2013
Commitments and Contingencies Disclosure [Abstract]
Consultancy agreement, term	6 months
Consultancy agreement, initial payment	$50,000
Consultancy agreement, additional payments	50,000
Shares issued for consultancy agreement	100,000
Research and development expenses		182,606
Cash payment obligations		200,000
Accrued expenses		$110,000

INCOME_TAXES_Narrative_Details

INCOME TAXES (Narrative) (Details)	12 Months Ended
	Dec. 31, 2014
INCOME TAXES [Abstract]
Expiration term	20 years

INCOME_TAXES_Schedule_of_Sourc

INCOME TAXES (Schedule of Sources and Tax Effects of Differences for Periods) (Details)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013
Sources and tax effects of the differences
Income tax provision at the federal statutory rate (as a percent)	39.00%	39.00%
Effect of operating losses (as a percent)	-39.00%	-39.00%
Effective income tax rate (as a percent)

INCOME_TAXES_Schedule_of_Chang

INCOME TAXES (Schedule of Changes in Cumulative Net Deferred Tax Assets) (Details) (USD $)	Dec. 31, 2014	Dec. 31, 2013
Net deferred tax assets
Net loss carry forward	$2,207,303	$156,603
Valuation allowance	-2,207,303	-11,301,282
Net deferred tax assets

INCOME_TAXES_Schedule_of_Recon

INCOME TAXES (Schedule of Reconciliation of Income Taxes Computed at Statutory Rate) (Details) (USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013
Reconciliation of income taxes computed at statutory rate
Tax at statutory rate	$799,773	$1,234
Valuation allowance	-799,773	-1,234
Income tax expense (benefit)

RELATED_PARTY_TRANSACTIONS_Det

RELATED PARTY TRANSACTIONS (Details) (USD $)	Dec. 31, 2014	Dec. 31, 2013
Related party transaction [Line Items]
Total due from related parties	$44,012	$8,862
Affiliated customer [Member]
Related party transaction [Line Items]
Total due from related parties	3,112
Lone Mountain [Member]
Related party transaction [Line Items]
Total due from related parties	40,900
MTA [Member]
Related party transaction [Line Items]
Total due from related parties		$8,862

DISCONTINUED_OPERATIONS_Detail

DISCONTINUED OPERATIONS (Details) (USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013	Mar. 31, 2014
DISCONTINUED OPERATIONS [Abstract]
Amount of payable owed to former officer and director, exchanged for assets sold			$15,000
Revenues	20,684	105,662
Operating expenses:
Selling, general and administrative	63,872	57,146
Depreciation		18,019
Loss on disposal of assets	15,704
Total operating expenses	79,576	75,165
Income (loss) from discontinued operations, before income taxes	-58,892	30,496
Provision for income taxes
Income (loss) from discontinued operations, net of income taxes	-58,892	30,496
Equipment		$17,616

SUBSEQUENT_EVENTS_Narrative_De

SUBSEQUENT EVENTS (Narrative) (Details) (USD $)	0 Months Ended				1 Months Ended	12 Months Ended	0 Months Ended
	Dec. 30, 2014	Oct. 24, 2014	Aug. 14, 2014	Aug. 15, 2014	Mar. 31, 2014	Dec. 31, 2014	Mar. 02, 2015	Feb. 10, 2015	Jan. 09, 2015
Subsequent Event [Line Items]
Number of shares of common stock issued					38,690,000
Value of shares of common stock issued
Number of shares of common stock issued for services	20,000	20,000	10,000	20,000
Value of shares of common stock issued for services	13,800	24,000	9,200	24,800		305,100
Subsequent Event [Member]
Subsequent Event [Line Items]
Number of shares of common stock issued for services							30,000
Value of shares of common stock issued for services							42,600
Subsequent Event [Member] | Typenex Co-Investment, LLC [Member]
Subsequent Event [Line Items]
Number of shares of common stock issued								621,000
Value of shares of common stock issued								$987,390
Subsequent Event [Member] | Warrant [Member] | Typenex Co-Investment, LLC [Member]
Subsequent Event [Line Items]
Number of warrants repurchased								170,044
Subsequent Event [Member] | Stock options [Member] | Stock Incentive Plan2014 [Member]
Subsequent Event [Line Items]
Fair value of option (in dollars per share)									$0.70
Vesting period									10 years
Subsequent Event [Member] | Messrs. Blackmon [Member] | Stock options [Member] | Stock Incentive Plan2014 [Member]
Subsequent Event [Line Items]
Number of shares awarded									200,000
Subsequent Event [Member] | Verzura [Member] | Stock options [Member] | Stock Incentive Plan2014 [Member]
Subsequent Event [Line Items]
Number of shares awarded									200,000
Subsequent Event [Member] | Ruby [Member] | Stock options [Member] | Stock Incentive Plan2014 [Member]
Subsequent Event [Line Items]
Number of shares awarded									200,000

SUBSEQUENT_EVENTS_Schedule_of_

SUBSEQUENT EVENTS (Schedule of Assumptions on Date of Valuation Utilizing Black Scholes Option Pricing Model for Fair Value of Each Stock Options) (Details) (Subsequent Event [Member], Stock options [Member], USD $)	0 Months Ended
	Jan. 09, 2015
Subsequent Event [Member] | Stock options [Member]
Subsequent Event [Line Items]
Stock price (in dollars per share)	$0.70
Exercise price (in dollars per share)	$0.70
Risk free interest rate (as a percent)	1.98%
Expected term (years)	10 years
Expected volatility (as a percent)	173.00%
Expected dividends (as a percent)	0.00%